ID

DB00232|APRD01104|DB00151|

名称

Methyclothiazide

描述

A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

cas号

135-07-9

唯一标识码

L3H46UAC61

状态

solid

组

withdrawn,

指示

For use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

药效学

Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs.

作用机制

Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

毒性

Acute oral toxicity (LD₅₀): >4000 mg/kg [Rat]. Symptoms of overdosage include electrolyte imbalance and signs of potassium deficiency such as confusion, dizziness, muscular weakness, and gastrointestinal disturbances.

代谢

吸收

Rapidly absorbed following oral administration.

半衰期

分类

description:This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
direct-parent:1,2,4-benzothiadiazine-1,1-dioxides
kingdom:Organic compounds
superclass:Organoheterocyclic compounds
class:Thiadiazines
subclass:Benzothiadiazines
alternative-parent:Alkyl chlorides
alternative-parent:Aminosulfonyl compounds
alternative-parent:Aryl chlorides
alternative-parent:Azacyclic compounds
alternative-parent:Benzenoids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organochlorides
alternative-parent:Organopnictogen compounds
alternative-parent:Organosulfonamides
alternative-parent:Secondary alkylarylamines
substituent:1,2,4-benzothiadiazine-1,1-dioxide
substituent:Alkyl chloride
substituent:Alkyl halide
substituent:Amine
substituent:Aminosulfonyl compound
substituent:Aromatic heteropolycyclic compound
substituent:Aryl chloride
substituent:Aryl halide
substituent:Azacycle
substituent:Benzenoid
substituent:Hydrocarbon derivative
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organic sulfonic acid or derivatives
substituent:Organochloride
substituent:Organohalogen compound
substituent:Organonitrogen compound
substituent:Organopnictogen compound
substituent:Organosulfonic acid amide
substituent:Organosulfonic acid or derivatives
substituent:Organosulfur compound
substituent:Secondary aliphatic/aromatic amine
substituent:Secondary amine
substituent:Sulfonyl

消除途径

种类

Amides
D000577
Benzothiadiazines
D001581
Cardiovascular Agents
D002317
Diuretics
D004232
Drugs causing inadvertant photosensitivity

Heterocyclic Compounds, Fused-Ring
D000072471
Hyperglycemia-Associated Agents

Hypotensive Agents

Increased Diuresis

Membrane Transport Modulators
D049990
Natriuretic Agents
D045283
Photosensitizing Agents
D017319
Sodium Chloride Symporter Inhibitors
D049993
Sulfonamides
D013449
Sulfones
D013450
Sulfur Compounds
D013457
Thiazides
D049971

盐类

蛋白质结合

清除

同义词

language:english; code:inn/usan; name;Methyclothiazide

国际品牌

AquatensenDureticEnduron

配送量

产品

name:Duretic 5mg
labeller:Abbott
ndc-id:
ndc-product-code:
dpd-id:00000485
ema-product-code:
ema-ma-number:
started-marketing-on:1960-12-31
ended-marketing-on:1999-08-09
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Enduronyl
labeller:Abbvie
ndc-id:
ndc-product-code:0074-6838
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1961-08-01
ended-marketing-on:2002-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA012775
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Enduronyl
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-3785
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1961-08-01
ended-marketing-on:2006-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA012775
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Enduronyl Forte
labeller:Abbvie
ndc-id:
ndc-product-code:0074-6854
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1961-08-01
ended-marketing-on:2001-04-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA012775
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Methyclothiazide
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-0160
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1982-08-17
ended-marketing-on:2019-12-31
dosage-form:Tablet
strength:5 mg/1
route:Oral
fda-application-number:ANDA087672
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Enduronyl
ingredients:Deserpidine + Methyclothiazide
name:Enduronyl Forte
ingredients:Deserpidine + Methyclothiazide
name:Enduronyl
ingredients:Deserpidine + Methyclothiazide
name:Methyclothiazide
ingredients:Methyclothiazide
name:Duretic 5mg
ingredients:Methyclothiazide

包装者

name:Ivax Pharmaceuticals
url:
name:Medisca Inc.
url:http://www.medisca.com
name:Mylan
url:http://www.mylan.com
name:Pharmaceutical Utilization Management Program VA Inc.
url:
name:Pharmedix
url:http://www.pharmedixrx.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Sandhills Packaging Inc.
url:http://www.sandhillspackaging.com

生产者

generic:否; url:; name;Medpointe pharmaceuticals medpointe healthcare inc
generic:否; url:; name;Abbott laboratories pharmaceutical products div
generic:是; url:; name;Ivax pharmaceuticals inc
generic:是; url:; name;Mylan pharmaceuticals inc
generic:是; url:; name;Par pharmaceutical inc
generic:是; url:; name;Sandoz inc
generic:是; url:; name;Usl pharma inc
generic:是; url:; name;Watson laboratories inc

价格

Methyclothiazide powder
11.32(单位：USD）
g
Enduron 5 mg tablet
0.77(单位：USD）
tablet
Methyclothiazide 5 mg tablet
0.77(单位：USD）
tablet

受影响的生物体

Humans and other mammals

剂量

form:Tablet
route:Oral
strength:
form:Tablet
route:Oral
strength:
form:Tablet
route:Oral
strength:5 mg/1

atc代码

Thiazides, plain
LOW-CEILING DIURETICS, THIAZIDES
DIURETICS
CARDIOVASCULAR SYSTEM
Thiazides and potassium in combination
LOW-CEILING DIURETICS, THIAZIDES
DIURETICS
CARDIOVASCULAR SYSTEM

fda标签

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00232.pdf?1265922749

专利

食物相互作用

药物相互作用

DB00476
The risk or severity of orthostatic hypotension and syncope can be increased when Methyclothiazide is combined with Duloxetine.
DB01235
The risk or severity of hypotension and orthostatic hypotension can be increased when Methyclothiazide is combined with Levodopa.
DB00734
Methyclothiazide may increase the hypotensive activities of Risperidone.
DB01342
Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Forasartan.
DB01349
Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Tasosartan.
DB06763
Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin.
DB08822
Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Azilsartan medoxomil.
DB09279
Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
DB00184
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicotine.
DB08999
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclopentamine.
DB00437
The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide.
DB00564
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.
DB00531
The risk or severity of granulocytopenia can be increased when Methyclothiazide is combined with Cyclophosphamide.
DB01119
The risk or severity of hypotension, hyperglycemia, and hyperuricemia can be increased when Methyclothiazide is combined with Diazoxide.
DB00204
The risk or severity of QTc prolongation can be increased when Methyclothiazide is combined with Dofetilide.
DB09083
The risk or severity of Cardiac Arrhythmia can be increased when Methyclothiazide is combined with Ivabradine.
DB14507
Methyclothiazide may decrease the excretion rate of Lithium citrate which could result in a higher serum level.
DB14509
Methyclothiazide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB14506
Methyclothiazide may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB00776
The risk or severity of hyponatremia can be increased when Methyclothiazide is combined with Oxcarbazepine.
DB00273
The risk or severity of hypokalemia can be increased when Methyclothiazide is combined with Topiramate.
DB00539
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Toremifene.
DB00563
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methotrexate.
DB00391
The risk or severity of orthostatic hypotension can be increased when Methyclothiazide is combined with Sulpiride.
DB01238
Aripiprazole may increase the hypotensive activities of Methyclothiazide.
DB14185
Aripiprazole lauroxil may increase the hypotensive activities of Methyclothiazide.
DB09220
Nicorandil may increase the hypotensive activities of Methyclothiazide.
DB00030
The therapeutic efficacy of Insulin human can be decreased when used in combination with Methyclothiazide.
DB00046
The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Methyclothiazide.
DB00047
The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Methyclothiazide.
DB00071
The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methyclothiazide.
DB00197
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Methyclothiazide.
DB00222
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.
DB00263
The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Methyclothiazide.
DB00280
The therapeutic efficacy of Disopyramide can be decreased when used in combination with Methyclothiazide.
DB00284
The therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide.
DB00359
The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Methyclothiazide.
DB00412
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.
DB00414
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide.
DB00468
The therapeutic efficacy of Quinine can be decreased when used in combination with Methyclothiazide.
DB00491
The therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.
DB00672
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.
DB00731
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide.
DB00738
The therapeutic efficacy of Pentamidine can be decreased when used in combination with Methyclothiazide.
DB00834
The therapeutic efficacy of Mifepristone can be decreased when used in combination with Methyclothiazide.
DB00839
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.
DB00912
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.
DB00914
The therapeutic efficacy of Phenformin can be decreased when used in combination with Methyclothiazide.
DB01015
The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Methyclothiazide.
DB01016
The therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.
DB01067
The therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.
DB01120
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Methyclothiazide.
DB01124
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.
DB01132
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.
DB01200
The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Methyclothiazide.
DB01251
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.
DB01252
The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methyclothiazide.
DB01261
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.
DB01268
The therapeutic efficacy of Sunitinib can be decreased when used in combination with Methyclothiazide.
DB01276
The therapeutic efficacy of Exenatide can be decreased when used in combination with Methyclothiazide.
DB01277
The therapeutic efficacy of Mecasermin can be decreased when used in combination with Methyclothiazide.
DB01278
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Methyclothiazide.
DB01289
The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Methyclothiazide.
DB01306
The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Methyclothiazide.
DB01307
The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Methyclothiazide.
DB01309
The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Methyclothiazide.
DB01382
The therapeutic efficacy of Glymidine can be decreased when used in combination with Methyclothiazide.
DB01700
The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methyclothiazide.
DB04830
The therapeutic efficacy of Buformin can be decreased when used in combination with Methyclothiazide.
DB04876
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.
DB04878
The therapeutic efficacy of Voglibose can be decreased when used in combination with Methyclothiazide.
DB05115
The therapeutic efficacy of NN344 can be decreased when used in combination with Methyclothiazide.
DB05819
The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Methyclothiazide.
DB06011
The therapeutic efficacy of AMG-222 can be decreased when used in combination with Methyclothiazide.
DB06127
The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Methyclothiazide.
DB06203
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.
DB06292
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methyclothiazide.
DB06335
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.
DB06655
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methyclothiazide.
DB08382
The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Methyclothiazide.
DB08882
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.
DB08907
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
DB08962
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Methyclothiazide.
DB09022
The therapeutic efficacy of Benfluorex can be decreased when used in combination with Methyclothiazide.
DB09043
The therapeutic efficacy of Albiglutide can be decreased when used in combination with Methyclothiazide.
DB09045
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.
DB09198
The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Methyclothiazide.
DB09199
The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Methyclothiazide.
DB09200
The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Methyclothiazide.
DB09201
The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methyclothiazide.
DB09265
The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Methyclothiazide.
DB09456
The therapeutic efficacy of Insulin beef can be decreased when used in combination with Methyclothiazide.
DB09564
The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Methyclothiazide.
DB11567
The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Methyclothiazide.
DB11568
The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Methyclothiazide.
DB11698
The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Methyclothiazide.
DB11723
The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Methyclothiazide.
DB11780
The therapeutic efficacy of Allicin can be decreased when used in combination with Methyclothiazide.
DB11824
The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Methyclothiazide.
DB11827
The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Methyclothiazide.
DB11898
The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Methyclothiazide.
DB11950
The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Methyclothiazide.
DB11992
The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Methyclothiazide.
DB12268
The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Methyclothiazide.
DB12412
The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Methyclothiazide.
DB12417
The therapeutic efficacy of Anagliptin can be decreased when used in combination with Methyclothiazide.
DB12625
The therapeutic efficacy of Evogliptin can be decreased when used in combination with Methyclothiazide.
DB12713
The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Methyclothiazide.
DB12781
The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methyclothiazide.
DB12935
The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Methyclothiazide.
DB13406
The therapeutic efficacy of Carbutamide can be decreased when used in combination with Methyclothiazide.
DB13446
The therapeutic efficacy of Guar gum can be decreased when used in combination with Methyclothiazide.
DB13675
The therapeutic efficacy of Metahexamide can be decreased when used in combination with Methyclothiazide.
DB13928
The therapeutic efficacy of Semaglutide can be decreased when used in combination with Methyclothiazide.
DB14027
The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Methyclothiazide.
DB14035
The therapeutic efficacy of Englitazone can be decreased when used in combination with Methyclothiazide.
DB15171
The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Methyclothiazide.
DB15217
The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Methyclothiazide.
DB00136
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Calcitriol.
DB00146
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Calcifediol.
DB00153
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Ergocalciferol.
DB00169
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Cholecalciferol.
DB00910
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Paricalcitol.
DB01070
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Dihydrotachysterol.
DB01436
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Alfacalcidol.
DB04258
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Seocalcitol.
DB04796
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Inecalcitol.
DB04891
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Becocalcidiol.
DB05295
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Eldecalcitol.
DB06117
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with 1alpha,24S-Dihydroxyvitamin D2.
DB06194
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Elocalcitol.
DB06272
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Maxacalcitol.
DB06410
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Doxercalciferol.
DB11094
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Vitamin D.
DB13097
The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with 1alpha-Hydroxyvitamin D5.
DB00176
The risk or severity of hyponatremia can be increased when Fluvoxamine is combined with Methyclothiazide.
DB00215
The risk or severity of hyponatremia can be increased when Citalopram is combined with Methyclothiazide.
DB00472
The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Methyclothiazide.
DB00656
The risk or severity of hyponatremia can be increased when Trazodone is combined with Methyclothiazide.
DB00715
The risk or severity of hyponatremia can be increased when Paroxetine is combined with Methyclothiazide.
DB01104
The risk or severity of hyponatremia can be increased when Sertraline is combined with Methyclothiazide.
DB01105
The risk or severity of hyponatremia can be increased when Sibutramine is combined with Methyclothiazide.
DB01149
The risk or severity of hyponatremia can be increased when Nefazodone is combined with Methyclothiazide.
DB01175
The risk or severity of hyponatremia can be increased when Escitalopram is combined with Methyclothiazide.
DB04832
The risk or severity of hyponatremia can be increased when Zimelidine is combined with Methyclothiazide.
DB04884
The risk or severity of hyponatremia can be increased when Dapoxetine is combined with Methyclothiazide.
DB04896
The risk or severity of hyponatremia can be increased when Milnacipran is combined with Methyclothiazide.
DB06700
The risk or severity of hyponatremia can be increased when Desvenlafaxine is combined with Methyclothiazide.
DB06731
The risk or severity of hyponatremia can be increased when Seproxetine is combined with Methyclothiazide.
DB08918
The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Methyclothiazide.
DB08953
The risk or severity of hyponatremia can be increased when Indalpine is combined with Methyclothiazide.
DB12693
The risk or severity of hyponatremia can be increased when Ritanserin is combined with Methyclothiazide.
DB13233
The risk or severity of hyponatremia can be increased when Alaproclate is combined with Methyclothiazide.
DB14209
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Trandolaprilat.
DB14210
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Moexiprilat.
DB14231
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Quinoline Yellow WS.
DB15565
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Cilazaprilat.
DB00209
The serum concentration of Methyclothiazide can be increased when it is combined with Trospium.
DB00219
The serum concentration of Methyclothiazide can be increased when it is combined with Oxyphenonium.
DB00246
The serum concentration of Methyclothiazide can be increased when it is combined with Ziprasidone.
DB00306
The serum concentration of Methyclothiazide can be increased when it is combined with Talbutal.
DB00332
The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium.
DB00334
The serum concentration of Methyclothiazide can be increased when it is combined with Olanzapine.
DB00340
The serum concentration of Methyclothiazide can be increased when it is combined with Metixene.
DB00342
The serum concentration of Methyclothiazide can be increased when it is combined with Terfenadine.
DB00354
The serum concentration of Methyclothiazide can be increased when it is combined with Buclizine.
DB00366
The serum concentration of Methyclothiazide can be increased when it is combined with Doxylamine.
DB00376
The serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.
DB00383
The serum concentration of Methyclothiazide can be increased when it is combined with Oxyphencyclimine.
DB00387
The serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.
DB00392
The serum concentration of Methyclothiazide can be increased when it is combined with Profenamine.
DB00416
The serum concentration of Methyclothiazide can be increased when it is combined with Metocurine iodide.
DB00420
The serum concentration of Methyclothiazide can be increased when it is combined with Promazine.
DB00424
The serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.
DB00434
The serum concentration of Methyclothiazide can be increased when it is combined with Cyproheptadine.
DB00462
The serum concentration of Methyclothiazide can be increased when it is combined with Methscopolamine bromide.
DB00463
The serum concentration of Methyclothiazide can be increased when it is combined with Metharbital.
DB00483
The serum concentration of Methyclothiazide can be increased when it is combined with Gallamine triethiodide.
DB00496
The serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.
DB00505
The serum concentration of Methyclothiazide can be increased when it is combined with Tridihexethyl.
DB00508
The serum concentration of Methyclothiazide can be increased when it is combined with Triflupromazine.
DB00514
The serum concentration of Methyclothiazide can be increased when it is combined with Dextromethorphan.
DB00517
The serum concentration of Methyclothiazide can be increased when it is combined with Anisotropine methylbromide.
DB00540
The serum concentration of Methyclothiazide can be increased when it is combined with Nortriptyline.
DB00543
The serum concentration of Methyclothiazide can be increased when it is combined with Amoxapine.
DB00565
The serum concentration of Methyclothiazide can be increased when it is combined with Cisatracurium.
DB00572
The serum concentration of Methyclothiazide can be increased when it is combined with Atropine.
DB00670
The serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.
DB00725
The serum concentration of Methyclothiazide can be increased when it is combined with Homatropine methylbromide.
DB00728
The serum concentration of Methyclothiazide can be increased when it is combined with Rocuronium.
DB00732
The serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.
DB00747
The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.
DB00767
The serum concentration of Methyclothiazide can be increased when it is combined with Benzquinamide.
DB00771
The serum concentration of Methyclothiazide can be increased when it is combined with Clidinium.
DB00777
The serum concentration of Methyclothiazide can be increased when it is combined with Propiomazine.
DB00810
The serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.
DB00835
The serum concentration of Methyclothiazide can be increased when it is combined with Brompheniramine.
DB00875
The serum concentration of Methyclothiazide can be increased when it is combined with Flupentixol.
DB00907
The serum concentration of Methyclothiazide can be increased when it is combined with Cocaine.
DB00940
The serum concentration of Methyclothiazide can be increased when it is combined with Methantheline.
DB00941
The serum concentration of Methyclothiazide can be increased when it is combined with Hexafluronium.
DB00942
The serum concentration of Methyclothiazide can be increased when it is combined with Cycrimine.
DB00967
The serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.
DB00986
The serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium.
DB01062
The serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.
DB01075
The serum concentration of Methyclothiazide can be increased when it is combined with Diphenhydramine.
DB01161
The serum concentration of Methyclothiazide can be increased when it is combined with Chloroprocaine.
DB01173
The serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.
DB01199
The serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.
DB01226
The serum concentration of Methyclothiazide can be increased when it is combined with Mivacurium.
DB01231
The serum concentration of Methyclothiazide can be increased when it is combined with Diphenidol.
DB01239
The serum concentration of Methyclothiazide can be increased when it is combined with Chlorprothixene.
DB01336
The serum concentration of Methyclothiazide can be increased when it is combined with Metocurine.
DB01337
The serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.
DB01338
The serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.
DB01339
The serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.
DB01352
The serum concentration of Methyclothiazide can be increased when it is combined with Aprobarbital.
DB01353
The serum concentration of Methyclothiazide can be increased when it is combined with Butobarbital.
DB01354
The serum concentration of Methyclothiazide can be increased when it is combined with Heptabarbital.
DB01403
The serum concentration of Methyclothiazide can be increased when it is combined with Methotrimeprazine.
DB01496
The serum concentration of Methyclothiazide can be increased when it is combined with Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione.
DB01591
The serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.
DB01625
The serum concentration of Methyclothiazide can be increased when it is combined with Isopropamide.
DB04834
The serum concentration of Methyclothiazide can be increased when it is combined with Rapacuronium.
DB04843
The serum concentration of Methyclothiazide can be increased when it is combined with Mepenzolate.
DB05710
The serum concentration of Methyclothiazide can be increased when it is combined with Gantacurium.
DB06153
The serum concentration of Methyclothiazide can be increased when it is combined with Pizotifen.
DB06787
The serum concentration of Methyclothiazide can be increased when it is combined with Hexocyclium.
DB08801
The serum concentration of Methyclothiazide can be increased when it is combined with Dimetindene.
DB08838
The serum concentration of Methyclothiazide can be increased when it is combined with Agmatine.
DB08997
The serum concentration of Methyclothiazide can be increased when it is combined with Dexetimide.
DB09023
The serum concentration of Methyclothiazide can be increased when it is combined with Benactyzine.
DB09076
The serum concentration of Methyclothiazide can be increased when it is combined with Umeclidinium.
DB09167
The serum concentration of Methyclothiazide can be increased when it is combined with Dosulepin.
DB09300
The serum concentration of Methyclothiazide can be increased when it is combined with Butylscopolamine.
DB11235
The serum concentration of Methyclothiazide can be increased when it is combined with Thonzylamine.
DB11315
The serum concentration of Methyclothiazide can be increased when it is combined with Methscopolamine.
DB11855
The serum concentration of Methyclothiazide can be increased when it is combined with Revefenacin.
DB12086
The serum concentration of Methyclothiazide can be increased when it is combined with Oxitropium.
DB12526
The serum concentration of Methyclothiazide can be increased when it is combined with Batefenterol.
DB12554
The serum concentration of Methyclothiazide can be increased when it is combined with Mebeverine.
DB13252
The serum concentration of Methyclothiazide can be increased when it is combined with Tropatepine.
DB13254
The serum concentration of Methyclothiazide can be increased when it is combined with Prifinium.
DB13295
The serum concentration of Methyclothiazide can be increased when it is combined with Atracurium.
DB13351
The serum concentration of Methyclothiazide can be increased when it is combined with Piperidolate.
DB13369
The serum concentration of Methyclothiazide can be increased when it is combined with Benzilone.
DB13380
The serum concentration of Methyclothiazide can be increased when it is combined with Difemerine.
DB13413
The serum concentration of Methyclothiazide can be increased when it is combined with Phenglutarimide.
DB13448
The serum concentration of Methyclothiazide can be increased when it is combined with Mazaticol.
DB13468
The serum concentration of Methyclothiazide can be increased when it is combined with Etybenzatropine.
DB13500
The serum concentration of Methyclothiazide can be increased when it is combined with Otilonium.
DB13505
The serum concentration of Methyclothiazide can be increased when it is combined with Emepronium.
DB13507
The serum concentration of Methyclothiazide can be increased when it is combined with Poldine.
DB13542
The serum concentration of Methyclothiazide can be increased when it is combined with Bevonium.
DB13581
The serum concentration of Methyclothiazide can be increased when it is combined with Rociverine.
DB13584
The serum concentration of Methyclothiazide can be increased when it is combined with Gallamine.
DB13619
The serum concentration of Methyclothiazide can be increased when it is combined with Bornaprine.
DB13636
The serum concentration of Methyclothiazide can be increased when it is combined with Etanautine.
DB13648
The serum concentration of Methyclothiazide can be increased when it is combined with Alcuronium.
DB13666
The serum concentration of Methyclothiazide can be increased when it is combined with Tiemonium iodide.
DB13678
The serum concentration of Methyclothiazide can be increased when it is combined with Dihexyverine.
DB13695
The serum concentration of Methyclothiazide can be increased when it is combined with Penthienate.
DB13720
The serum concentration of Methyclothiazide can be increased when it is combined with Diphemanil.
DB13738
The serum concentration of Methyclothiazide can be increased when it is combined with Camylofin.
DB13759
The serum concentration of Methyclothiazide can be increased when it is combined with Fenpiverinium.
DB13769
The serum concentration of Methyclothiazide can be increased when it is combined with Emetonium iodide.
DB13844
The serum concentration of Methyclothiazide can be increased when it is combined with Pipenzolate.
DB13850
The serum concentration of Methyclothiazide can be increased when it is combined with Timepidium.
DB09007
The serum concentration of Methyclothiazide can be increased when it is combined with Chlorphenoxamine.
DB01009
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methyclothiazide.
DB09214
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Methyclothiazide.
DB00898
The risk or severity of hypotension and orthostatic hypotension can be increased when Ethanol is combined with Methyclothiazide.
DB00159
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icosapent.
DB00244
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.
DB00461
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.
DB00465
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.
DB00469
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.
DB00482
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.
DB00500
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.
DB00533
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Rofecoxib.
DB00554
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.
DB00573
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.
DB00580
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.
DB00586
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.
DB00712
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.
DB00749
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.
DB00784
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.
DB00795
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.
DB00812
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.
DB00821
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.
DB00861
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.
DB00936
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylic acid.
DB00939
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.
DB00991
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.
DB01014
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.
DB01050
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.
DB01250
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.
DB01283
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lumiracoxib.
DB01397
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.
DB01399
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.
DB01401
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Choline magnesium trisalicylate.
DB01419
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antrafenine.
DB01424
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aminophenazone.
DB01435
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.
DB01600
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.
DB01628
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.
DB02224
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Taxifolin.
DB03585
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.
DB04725
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Licofelone.
DB04743
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.
DB04812
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benoxaprofen.
DB04817
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.
DB04828
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.
DB05095
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Cimicoxib.
DB06725
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.
DB06736
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aceclofenac.
DB08439
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.
DB08797
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.
DB08940
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Kebuzone.
DB08942
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Isoxicam.
DB08951
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indoprofen.
DB08955
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuproxam.
DB08976
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Floctafenine.
DB08981
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen.
DB08984
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etofenamate.
DB08991
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Epirizole.
DB09084
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benzydamine.
DB09213
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dexibuprofen.
DB09215
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Droxicam.
DB09216
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic acid.
DB09217
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Firocoxib.
DB09218
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Clonixin.
DB09285
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Morniflumate.
DB09288
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propacetamol.
DB09295
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Talniflumate.
DB11455
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Robenacoxib.
DB11466
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tepoxalin.
DB11518
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flunixin.
DB12399
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Polmacoxib.
DB12445
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nitroaspirin.
DB12545
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indobufen.
DB12610
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ebselen.
DB13001
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tinoridine.
DB13167
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alclofenac.
DB13217
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fentiazac.
DB13232
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suxibuzone.
DB13286
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bumadizone.
DB13314
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alminoprofen.
DB13371
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Difenpiramide.
DB13407
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nifenazone.
DB13432
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lonazolac.
DB13481
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenidap.
DB13524
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Propyphenazone.
DB13527
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Proglumetacin.
DB13538
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Guacetisal.
DB13544
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ethenzamide.
DB13612
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carbaspirin calcium.
DB13629
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mofebutazone.
DB13649
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Proquazone.
DB13657
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benorilate.
DB13722
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirprofen.
DB13860
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Imidazole salicylate.
DB14059
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with SC-236.
DB14060
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with NS-398.
DB14938
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen axetil.
DB09212
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Loxoprofen.
DB00241
The risk or severity of hypotension and orthostatic hypotension can be increased when Butalbital is combined with Methyclothiazide.
DB00312
The risk or severity of hypotension and orthostatic hypotension can be increased when Pentobarbital is combined with Methyclothiazide.
DB00418
The risk or severity of hypotension and orthostatic hypotension can be increased when Secobarbital is combined with Methyclothiazide.
DB00474
The risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Methyclothiazide.
DB00599
The risk or severity of hypotension and orthostatic hypotension can be increased when Thiopental is combined with Methyclothiazide.
DB00794
The risk or severity of hypotension and orthostatic hypotension can be increased when Primidone is combined with Methyclothiazide.
DB00849
The risk or severity of hypotension and orthostatic hypotension can be increased when Methylphenobarbital is combined with Methyclothiazide.
DB01154
The risk or severity of hypotension and orthostatic hypotension can be increased when Thiamylal is combined with Methyclothiazide.
DB01174
The risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Methyclothiazide.
DB01351
The risk or severity of hypotension and orthostatic hypotension can be increased when Amobarbital is combined with Methyclothiazide.
DB01355
The risk or severity of hypotension and orthostatic hypotension can be increased when Hexobarbital is combined with Methyclothiazide.
DB01483
The risk or severity of hypotension and orthostatic hypotension can be increased when Barbital is combined with Methyclothiazide.
DB09001
The risk or severity of hypotension and orthostatic hypotension can be increased when Barbexaclone is combined with Methyclothiazide.
DB00258
Methyclothiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00326
Methyclothiazide may decrease the excretion rate of Calcium glucoheptonate which could result in a higher serum level.
DB01164
Methyclothiazide may decrease the excretion rate of Calcium chloride which could result in a higher serum level.
DB01373
Methyclothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.
DB06724
Methyclothiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.
DB11093
Methyclothiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.
DB11126
Methyclothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.
DB11348
Methyclothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.
DB13142
Methyclothiazide may decrease the excretion rate of Calcium glubionate anhydrous which could result in a higher serum level.
DB13231
Methyclothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.
DB13365
Methyclothiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.
DB13590
Methyclothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.
DB13800
Methyclothiazide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.
DB14577
Methyclothiazide may decrease the excretion rate of Calcium cation which could result in a higher serum level.
DB14684
Methyclothiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level.
DB00091
The risk or severity of renal failure can be increased when Methyclothiazide is combined with Cyclosporine.
DB00375
Colestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00658
Sevelamer can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00930
Colesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01432
Cholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00182
Amphetamine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00601
Linezolid may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00614
Furazolidone may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00721
Procaine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00752
Tranylcypromine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00780
Phenelzine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00805
Minaprine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB01037
Selegiline may increase the orthostatic hypotensive activities of Methyclothiazide.
DB01168
Procarbazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB01171
Moclobemide may increase the orthostatic hypotensive activities of Methyclothiazide.
DB01247
Isocarboxazid may increase the orthostatic hypotensive activities of Methyclothiazide.
DB01367
Rasagiline may increase the orthostatic hypotensive activities of Methyclothiazide.
DB04017
Clorgiline may increase the orthostatic hypotensive activities of Methyclothiazide.
DB04818
Iproniazid may increase the orthostatic hypotensive activities of Methyclothiazide.
DB04820
Nialamide may increase the orthostatic hypotensive activities of Methyclothiazide.
DB06654
Safinamide may increase the orthostatic hypotensive activities of Methyclothiazide.
DB08550
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09241
Methylene blue may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09243
Hydracarbazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09244
Pirlindole may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09245
Toloxatone may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09246
Benmoxin may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09248
Mebanazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09249
Octamoxin may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09250
Pheniprazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09251
Phenoxypropazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09252
Pivhydrazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09253
Safrazine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB09254
Caroxazone may increase the orthostatic hypotensive activities of Methyclothiazide.
DB13875
Harmaline may increase the orthostatic hypotensive activities of Methyclothiazide.
DB13876
Brofaromine may increase the orthostatic hypotensive activities of Methyclothiazide.
DB00221
Isoetharine may increase the hypokalemic activities of Methyclothiazide.
DB00397
Phenylpropanolamine may increase the hypokalemic activities of Methyclothiazide.
DB00816
Orciprenaline may increase the hypokalemic activities of Methyclothiazide.
DB00867
Ritodrine may increase the hypokalemic activities of Methyclothiazide.
DB00901
Bitolterol may increase the hypokalemic activities of Methyclothiazide.
DB00938
Salmeterol may increase the hypokalemic activities of Methyclothiazide.
DB00983
Formoterol may increase the hypokalemic activities of Methyclothiazide.
DB01064
Isoprenaline may increase the hypokalemic activities of Methyclothiazide.
DB01102
Arbutamine may increase the hypokalemic activities of Methyclothiazide.
DB01288
Fenoterol may increase the hypokalemic activities of Methyclothiazide.
DB01291
Pirbuterol may increase the hypokalemic activities of Methyclothiazide.
DB01363
Ephedra sinica root may increase the hypokalemic activities of Methyclothiazide.
DB01366
Procaterol may increase the hypokalemic activities of Methyclothiazide.
DB01407
Clenbuterol may increase the hypokalemic activities of Methyclothiazide.
DB01408
Bambuterol may increase the hypokalemic activities of Methyclothiazide.
DB05039
Indacaterol may increase the hypokalemic activities of Methyclothiazide.
DB08957
Hexoprenaline may increase the hypokalemic activities of Methyclothiazide.
DB09080
Olodaterol may increase the hypokalemic activities of Methyclothiazide.
DB09273
Doxofylline may increase the hypokalemic activities of Methyclothiazide.
DB11871
PF-00610355 may increase the hypokalemic activities of Methyclothiazide.
DB12100
Abediterol may increase the hypokalemic activities of Methyclothiazide.
DB00086
The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.
DB00268
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropinirole.
DB00297
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bupivacaine.
DB00384
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.
DB00421
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.
DB00486
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nabilone.
DB00489
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.
DB00594
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride.
DB00679
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thioridazine.
DB00697
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.
DB00703
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.
DB00714
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apomorphine.
DB00753
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoflurane.
DB00755
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tretinoin.
DB00818
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propofol.
DB00872
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Conivaptan.
DB00883
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide dinitrate.
DB00903
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.
DB00922
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levosimendan.
DB00975
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.
DB01041
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thalidomide.
DB01088
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Iloprost.
DB01113
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.
DB01118
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiodarone.
DB01143
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amifostine.
DB01144
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide.
DB01159
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Halothane.
DB01189
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Desflurane.
DB01229
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Paclitaxel.
DB01236
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sevoflurane.
DB01282
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbetocin.
DB01612
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amyl Nitrite.
DB04899
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nesiritide.
DB05271
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Rotigotine.
DB08935
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Obinutuzumab.
DB08941
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoxsuprine.
DB09077
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.
DB09112
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitrous acid.
DB09227
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Barnidipine.
DB09232
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cilnidipine.
DB09286
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pipamperone.
DB09449
Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.
DB13783
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acemetacin.
DB09236
Methyclothiazide may increase the hypotensive activities of Lacidipine.
DB00581
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lactulose.
DB00653
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium sulfate.
DB00742
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.
DB01046
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lubiprostone.
DB01079
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tegaserod.
DB01377
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium oxide.
DB01378
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium cation.
DB01593
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Zinc.
DB01638
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sorbitol.
DB04816
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dantron.
DB04823
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oxyphenisatin.
DB04824
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Phenolphthalein.
DB06480
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prucalopride.
DB07715
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Emodin.
DB08890
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Linaclotide.
DB09020
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisacodyl.
DB09104
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium hydroxide.
DB09219
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoxatin.
DB09268
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Picosulfuric acid.
DB09281
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium trisilicate.
DB09287
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Polyethylene glycol.
DB09311
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Polycarbophil.
DB09409
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium acetate tetrahydrate.
DB09413
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Monopotassium phosphate.
DB09414
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipotassium phosphate.
DB09462
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Glycerin.
DB09472
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium sulfate.
DB09481
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium carbonate.
DB09483
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Potassium lactate.
DB09484
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium fluorophosphate.
DB11057
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mineral oil.
DB11059
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carboxymethylcellulose.
DB11089
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Docusate.
DB11097
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Plantago seed.
DB11110
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium citrate.
DB11113
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Castor oil.
DB11189
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium glycinate.
DB11228
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methylcellulose.
DB11365
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sennosides.
DB12942
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lactitol.
DB13170
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Plecanatide.
DB13180
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Gluconic Acid.
DB13486
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium peroxide.
DB13526
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pentaerithrityl.
DB13707
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium tartrate.
DB13996
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium acetate.
DB14232
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deacetylbisacodyl.
DB14482
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium ascorbate.
DB14499
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Potassium sulfate.
DB14502
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium phosphate, dibasic.
DB14503
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium phosphate, monobasic, unspecified form.
DB14504
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium phosphate, dibasic, unspecified form.
DB14516
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium cation.
DB14585
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Plantago ovata seed.
DB14627
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oxyphenisatin acetate.
DB14963
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Konjac mannan.
DB15477
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Alloin.
DB15478
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Frangula purshiana bark.
DB11622
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dehydrocholic acid.
DB14546
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulfate ion.
DB00245
Benzatropine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00321
Amitriptyline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00555
Lamotrigine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00782
Propantheline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00804
Dicyclomine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00908
Quinidine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00934
Maprotiline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01036
Tolterodine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01069
Promethazine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01142
Doxepin may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01148
Flavoxate may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01151
Desipramine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01409
Tiotropium may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB06702
Fesoterodine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB08897
Aclidinium may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB09089
Trimebutine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB09262
Imidafenacin may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB12278
Propiverine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00841
Dobutamine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00871
Terbutaline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01001
Salbutamol may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB01274
Arformoterol may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB09082
Vilanterol may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB11587
Etafedrine may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB13139
Levosalbutamol may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041
Aldesleukin may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00296
Methyclothiazide may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.
DB00323
Methyclothiazide may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.
DB00363
Methyclothiazide may increase the excretion rate of Clozapine which could result in a lower serum level and potentially a reduction in efficacy.
DB00413
Methyclothiazide may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.
DB00435
Methyclothiazide may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.
DB00458
Methyclothiazide may increase the excretion rate of Imipramine which could result in a lower serum level and potentially a reduction in efficacy.
DB00477
Methyclothiazide may increase the excretion rate of Chlorpromazine which could result in a lower serum level and potentially a reduction in efficacy.
DB00631
Methyclothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.
DB00633
Methyclothiazide may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.
DB00661
Methyclothiazide may increase the excretion rate of Verapamil which could result in a lower serum level and potentially a reduction in efficacy.
DB00706
Methyclothiazide may increase the excretion rate of Tamsulosin which could result in a lower serum level and potentially a reduction in efficacy.
DB00887
Methyclothiazide may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB01002
Methyclothiazide may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.
DB01020
Methyclothiazide may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.
DB01115
Methyclothiazide may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.
DB01169
Methyclothiazide may increase the excretion rate of Arsenic trioxide which could result in a lower serum level and potentially a reduction in efficacy.
DB01224
Methyclothiazide may increase the excretion rate of Quetiapine which could result in a lower serum level and potentially a reduction in efficacy.
DB01242
Methyclothiazide may increase the excretion rate of Clomipramine which could result in a lower serum level and potentially a reduction in efficacy.
DB04920
Methyclothiazide may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.
DB09204
Methyclothiazide may increase the excretion rate of Arotinolol which could result in a lower serum level and potentially a reduction in efficacy.
DB09292
Methyclothiazide may increase the excretion rate of Sacubitril which could result in a lower serum level and potentially a reduction in efficacy.
DB00081
Methyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.
DB00262
Methyclothiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
DB00322
Methyclothiazide may increase the excretion rate of Floxuridine which could result in a lower serum level and potentially a reduction in efficacy.
DB00380
Methyclothiazide may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.
DB00398
Methyclothiazide may increase the excretion rate of Sorafenib which could result in a lower serum level and potentially a reduction in efficacy.
DB00441
Methyclothiazide may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.
DB00480
Methyclothiazide may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.
DB00501
Methyclothiazide may increase the excretion rate of Cimetidine which could result in a lower serum level and potentially a reduction in efficacy.
DB00515
Methyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
DB00552
Methyclothiazide may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.
DB00642
Methyclothiazide may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.
DB00763
Methyclothiazide may increase the excretion rate of Methimazole which could result in a lower serum level and potentially a reduction in efficacy.
DB00851
Methyclothiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
DB00853
Methyclothiazide may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.
DB00928
Methyclothiazide may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.
DB00958
Methyclothiazide may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.
DB01030
Methyclothiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
DB01099
Methyclothiazide may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.
DB01101
Methyclothiazide may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.
DB01181
Methyclothiazide may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.
DB08877
Methyclothiazide may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
DB08910
Methyclothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
DB01183
Naloxone may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007
Methyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00014
Methyclothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017
Methyclothiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035
Methyclothiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00080
Methyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DB00115
Methyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
DB00158
Methyclothiazide may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00165
Methyclothiazide may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.
DB00181
Methyclothiazide may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy.
DB00185
Methyclothiazide may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.
DB00186
Methyclothiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00190
Methyclothiazide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy.
DB00196
Methyclothiazide may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy.
DB00198
Methyclothiazide may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.
DB00200
Methyclothiazide may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.
DB00208
Methyclothiazide may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.
DB00213
Methyclothiazide may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.
DB00225
Methyclothiazide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00230
Methyclothiazide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy.
DB00231
Methyclothiazide may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00235
Methyclothiazide may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.
DB00237
Methyclothiazide may increase the excretion rate of Butabarbital which could result in a lower serum level and potentially a reduction in efficacy.
DB00243
Methyclothiazide may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy.
DB00254
Methyclothiazide may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.
DB00271
Methyclothiazide may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.
DB00279
Methyclothiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.
DB00285
Methyclothiazide may increase the excretion rate of Venlafaxine which could result in a lower serum level and potentially a reduction in efficacy.
DB00286
Methyclothiazide may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.
DB00289
Methyclothiazide may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.
DB00290
Methyclothiazide may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.
DB00292
Methyclothiazide may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.
DB00294
Methyclothiazide may increase the excretion rate of Etonogestrel which could result in a lower serum level and potentially a reduction in efficacy.
DB00300
Methyclothiazide may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.
DB00303
Methyclothiazide may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.
DB00308
Methyclothiazide may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.
DB00314
Methyclothiazide may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.
DB00316
Methyclothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
DB00319
Methyclothiazide may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.
DB00330
Methyclothiazide may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.
DB00339
Methyclothiazide may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00341
Methyclothiazide may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.
DB00349
Methyclothiazide may increase the excretion rate of Clobazam which could result in a lower serum level and potentially a reduction in efficacy.
DB00351
Methyclothiazide may increase the excretion rate of Megestrol acetate which could result in a lower serum level and potentially a reduction in efficacy.
DB00355
Methyclothiazide may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.
DB00356
Methyclothiazide may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00364
Methyclothiazide may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.
DB00369
Methyclothiazide may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.
DB00372
Methyclothiazide may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.
DB00377
Methyclothiazide may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.
DB00402
Methyclothiazide may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.
DB00404
Methyclothiazide may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.
DB00415
Methyclothiazide may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.
DB00422
Methyclothiazide may increase the excretion rate of Methylphenidate which could result in a lower serum level and potentially a reduction in efficacy.
DB00432
Methyclothiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.
DB00438
Methyclothiazide may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.
DB00440
Methyclothiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.
DB00490
Methyclothiazide may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.
DB00499
Methyclothiazide may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00502
Methyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
DB00512
Methyclothiazide may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.
DB00535
Methyclothiazide may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.
DB00537
Methyclothiazide may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.
DB00548
Methyclothiazide may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00553
Methyclothiazide may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.
DB00558
Methyclothiazide may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.
DB00567
Methyclothiazide may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.
DB00569
Methyclothiazide may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.
DB00577
Methyclothiazide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.
DB00583
Methyclothiazide may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.
DB00597
Methyclothiazide may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.
DB00603
Methyclothiazide may increase the excretion rate of Medroxyprogesterone acetate which could result in a lower serum level and potentially a reduction in efficacy.
DB00608
Methyclothiazide may increase the excretion rate of Chloroquine which could result in a lower serum level and potentially a reduction in efficacy.
DB00624
Methyclothiazide may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.
DB00628
Methyclothiazide may increase the excretion rate of Clorazepic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00651
Methyclothiazide may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00660
Methyclothiazide may increase the excretion rate of Metaxalone which could result in a lower serum level and potentially a reduction in efficacy.
DB00665
Methyclothiazide may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00669
Methyclothiazide may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.
DB00682
Methyclothiazide may increase the excretion rate of Warfarin which could result in a lower serum level and potentially a reduction in efficacy.
DB00683
Methyclothiazide may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.
DB00688
Methyclothiazide may increase the excretion rate of Mycophenolate mofetil which could result in a lower serum level and potentially a reduction in efficacy.
DB00690
Methyclothiazide may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00698
Methyclothiazide may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.
DB00709
Methyclothiazide may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.
DB00713
Methyclothiazide may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.
DB00716
Methyclothiazide may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.
DB00730
Methyclothiazide may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.
DB00733
Methyclothiazide may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.
DB00743
Methyclothiazide may increase the excretion rate of Gadobenic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00759
Methyclothiazide may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.
DB00760
Methyclothiazide may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.
DB00761
Methyclothiazide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.
DB00775
Methyclothiazide may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.
DB00783
Methyclothiazide may increase the excretion rate of Estradiol which could result in a lower serum level and potentially a reduction in efficacy.
DB00787
Methyclothiazide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.
DB00789
Methyclothiazide may increase the excretion rate of Gadopentetic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00806
Methyclothiazide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00811
Methyclothiazide may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.
DB00828
Methyclothiazide may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.
DB00829
Methyclothiazide may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00833
Methyclothiazide may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.
DB00842
Methyclothiazide may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00863
Methyclothiazide may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.
DB00879
Methyclothiazide may increase the excretion rate of Emtricitabine which could result in a lower serum level and potentially a reduction in efficacy.
DB00894
Methyclothiazide may increase the excretion rate of Testolactone which could result in a lower serum level and potentially a reduction in efficacy.
DB00897
Methyclothiazide may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.
DB00900
Methyclothiazide may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.
DB00909
Methyclothiazide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00911
Methyclothiazide may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.
DB00915
Methyclothiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.
DB00918
Methyclothiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.
DB00951
Methyclothiazide may increase the excretion rate of Isoniazid which could result in a lower serum level and potentially a reduction in efficacy.
DB00953
Methyclothiazide may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.
DB00961
Methyclothiazide may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.
DB00962
Methyclothiazide may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.
DB00980
Methyclothiazide may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.
DB00982
Methyclothiazide may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.
DB00988
Methyclothiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.
DB00993
Methyclothiazide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.
DB00995
Methyclothiazide may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.
DB01004
Methyclothiazide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.
DB01010
Methyclothiazide may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.
DB01011
Methyclothiazide may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.
DB01022
Methyclothiazide may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.
DB01024
Methyclothiazide may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB01035
Methyclothiazide may increase the excretion rate of Procainamide which could result in a lower serum level and potentially a reduction in efficacy.
DB01039
Methyclothiazide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.
DB01043
Methyclothiazide may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.
DB01048
Methyclothiazide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
DB01060
Methyclothiazide may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.
DB01068
Methyclothiazide may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01093
Methyclothiazide may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.
DB01129
Methyclothiazide may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.
DB01133
Methyclothiazide may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB01135
Methyclothiazide may increase the excretion rate of Doxacurium which could result in a lower serum level and potentially a reduction in efficacy.
DB01137
Methyclothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.
DB01140
Methyclothiazide may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.
DB01156
Methyclothiazide may increase the excretion rate of Bupropion which could result in a lower serum level and potentially a reduction in efficacy.
DB01157
Methyclothiazide may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.
DB01166
Methyclothiazide may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.
DB01205
Methyclothiazide may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.
DB01212
Methyclothiazide may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.
DB01213
Methyclothiazide may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.
DB01215
Methyclothiazide may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.
DB01221
Methyclothiazide may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.
DB01233
Methyclothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.
DB01241
Methyclothiazide may increase the excretion rate of Gemfibrozil which could result in a lower serum level and potentially a reduction in efficacy.
DB01249
Methyclothiazide may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.
DB01267
Methyclothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy.
DB01273
Methyclothiazide may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.
DB01330
Methyclothiazide may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.
DB01333
Methyclothiazide may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.
DB01415
Methyclothiazide may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.
DB01420
Methyclothiazide may increase the excretion rate of Testosterone propionate which could result in a lower serum level and potentially a reduction in efficacy.
DB01427
Methyclothiazide may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.
DB01428
Methyclothiazide may increase the excretion rate of Oxybenzone which could result in a lower serum level and potentially a reduction in efficacy.
DB01431
Methyclothiazide may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.
DB01550
Methyclothiazide may increase the excretion rate of Fenproporex which could result in a lower serum level and potentially a reduction in efficacy.
DB01558
Methyclothiazide may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01563
Methyclothiazide may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.
DB01577
Methyclothiazide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
DB01587
Methyclothiazide may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.
DB01610
Methyclothiazide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.
DB01656
Methyclothiazide may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.
DB01685
Methyclothiazide may increase the excretion rate of Topiroxostat which could result in a lower serum level and potentially a reduction in efficacy.
DB04574
Methyclothiazide may increase the excretion rate of Estrone sulfate which could result in a lower serum level and potentially a reduction in efficacy.
DB04871
Methyclothiazide may increase the excretion rate of Lorcaserin which could result in a lower serum level and potentially a reduction in efficacy.
DB04895
Methyclothiazide may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.
DB04953
Methyclothiazide may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.
DB05018
Methyclothiazide may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.
DB05541
Methyclothiazide may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.
DB05676
Methyclothiazide may increase the excretion rate of Apremilast which could result in a lower serum level and potentially a reduction in efficacy.
DB06154
Methyclothiazide may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.
DB06186
Methyclothiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.
DB06196
Methyclothiazide may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.
DB06209
Methyclothiazide may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.
DB06211
Methyclothiazide may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.
DB06228
Methyclothiazide may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.
DB06230
Methyclothiazide may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.
DB06282
Methyclothiazide may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.
DB06402
Methyclothiazide may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.
DB06623
Methyclothiazide may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.
DB06637
Methyclothiazide may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.
DB06695
Methyclothiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.
DB06705
Methyclothiazide may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.
DB06710
Methyclothiazide may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.
DB06767
Methyclothiazide may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.
DB06782
Methyclothiazide may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.
DB06796
Methyclothiazide may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.
DB06800
Methyclothiazide may increase the excretion rate of Methylnaltrexone which could result in a lower serum level and potentially a reduction in efficacy.
DB06809
Methyclothiazide may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.
DB06813
Methyclothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
DB06823
Methyclothiazide may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.
DB06824
Methyclothiazide may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.
DB08824
Methyclothiazide may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.
DB08826
Methyclothiazide may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.
DB08840
Methyclothiazide may increase the excretion rate of N-methylnicotinamide which could result in a lower serum level and potentially a reduction in efficacy.
DB08872
Methyclothiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.
DB08893
Methyclothiazide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy.
DB08894
Methyclothiazide may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.
DB08899
Methyclothiazide may increase the excretion rate of Enzalutamide which could result in a lower serum level and potentially a reduction in efficacy.
DB08900
Methyclothiazide may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.
DB08904
Methyclothiazide may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.
DB08905
Methyclothiazide may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.
DB08909
Methyclothiazide may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.
DB08911
Methyclothiazide may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.
DB08934
Methyclothiazide may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.
DB08996
Methyclothiazide may increase the excretion rate of Dimetacrine which could result in a lower serum level and potentially a reduction in efficacy.
DB09027
Methyclothiazide may increase the excretion rate of Ledipasvir which could result in a lower serum level and potentially a reduction in efficacy.
DB09050
Methyclothiazide may increase the excretion rate of Ceftolozane which could result in a lower serum level and potentially a reduction in efficacy.
DB09066
Methyclothiazide may increase the excretion rate of Corifollitropin alfa which could result in a lower serum level and potentially a reduction in efficacy.
DB09068
Methyclothiazide may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.
DB09071
Methyclothiazide may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.
DB09075
Methyclothiazide may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.
DB09081
Methyclothiazide may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.
DB09103
Methyclothiazide may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.
DB09106
Methyclothiazide may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.
DB09111
Methyclothiazide may increase the excretion rate of Pentastarch which could result in a lower serum level and potentially a reduction in efficacy.
DB09118
Methyclothiazide may increase the excretion rate of Stiripentol which could result in a lower serum level and potentially a reduction in efficacy.
DB09121
Methyclothiazide may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.
DB09123
Methyclothiazide may increase the excretion rate of Dienogest which could result in a lower serum level and potentially a reduction in efficacy.
DB09129
Methyclothiazide may increase the excretion rate of Chromic chloride which could result in a lower serum level and potentially a reduction in efficacy.
DB09132
Methyclothiazide may increase the excretion rate of Gadoteric acid which could result in a lower serum level and potentially a reduction in efficacy.
DB09133
Methyclothiazide may increase the excretion rate of Iothalamic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB09134
Methyclothiazide may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.
DB09135
Methyclothiazide may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.
DB09136
Methyclothiazide may increase the excretion rate of Isosulfan blue which could result in a lower serum level and potentially a reduction in efficacy.
DB09137
Methyclothiazide may increase the excretion rate of Technetium Tc-99m mebrofenin which could result in a lower serum level and potentially a reduction in efficacy.
DB09139
Methyclothiazide may increase the excretion rate of Technetium Tc-99m oxidronate which could result in a lower serum level and potentially a reduction in efficacy.
DB09148
Methyclothiazide may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.
DB09149
Methyclothiazide may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.
DB09156
Methyclothiazide may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.
DB09163
Methyclothiazide may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.
DB09165
Methyclothiazide may increase the excretion rate of Technetium Tc-99m pyrophosphate which could result in a lower serum level and potentially a reduction in efficacy.
DB09185
Methyclothiazide may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.
DB09194
Methyclothiazide may increase the excretion rate of Etoperidone which could result in a lower serum level and potentially a reduction in efficacy.
DB09195
Methyclothiazide may increase the excretion rate of Lorpiprazole which could result in a lower serum level and potentially a reduction in efficacy.
DB09205
Methyclothiazide may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.
DB09209
Methyclothiazide may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.
DB09210
Methyclothiazide may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.
DB09223
Methyclothiazide may increase the excretion rate of Blonanserin which could result in a lower serum level and potentially a reduction in efficacy.
DB09224
Methyclothiazide may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.
DB09255
Methyclothiazide may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.
DB09256
Methyclothiazide may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.
DB09257
Methyclothiazide may increase the excretion rate of Gimeracil which could result in a lower serum level and potentially a reduction in efficacy.
DB09264
Methyclothiazide may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.
DB09276
Methyclothiazide may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.
DB09277
Methyclothiazide may increase the excretion rate of Choline C 11 which could result in a lower serum level and potentially a reduction in efficacy.
DB09301
Methyclothiazide may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.
DB09317
Methyclothiazide may increase the excretion rate of Synthetic Conjugated Estrogens, A which could result in a lower serum level and potentially a reduction in efficacy.
DB09318
Methyclothiazide may increase the excretion rate of Synthetic Conjugated Estrogens, B which could result in a lower serum level and potentially a reduction in efficacy.
DB09320
Methyclothiazide may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.
DB09324
Methyclothiazide may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.
DB09325
Methyclothiazide may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.
DB09329
Methyclothiazide may increase the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.
DB09338
Methyclothiazide may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB09344
Methyclothiazide may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.
DB09357
Methyclothiazide may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.
DB09394
Methyclothiazide may increase the excretion rate of Phosphoric acid which could result in a lower serum level and potentially a reduction in efficacy.
DB09395
Methyclothiazide may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.
DB09407
Methyclothiazide may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.
DB09418
Methyclothiazide may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.
DB09488
Methyclothiazide may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.
DB09496
Methyclothiazide may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.
DB09502
Methyclothiazide may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.
DB09546
Methyclothiazide may increase the excretion rate of Iobenguane sulfate I-123 which could result in a lower serum level and potentially a reduction in efficacy.
DB09570
Methyclothiazide may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.
DB11077
Methyclothiazide may increase the excretion rate of Polyethylene glycol 400 which could result in a lower serum level and potentially a reduction in efficacy.
DB11098
Methyclothiazide may increase the excretion rate of Potassium bicarbonate which could result in a lower serum level and potentially a reduction in efficacy.
DB11102
Methyclothiazide may increase the excretion rate of N-acetyltyrosine which could result in a lower serum level and potentially a reduction in efficacy.
DB11114
Methyclothiazide may increase the excretion rate of Eucalyptus oil which could result in a lower serum level and potentially a reduction in efficacy.
DB11127
Methyclothiazide may increase the excretion rate of Selenious acid which could result in a lower serum level and potentially a reduction in efficacy.
DB11135
Methyclothiazide may increase the excretion rate of Selenium which could result in a lower serum level and potentially a reduction in efficacy.
DB11136
Methyclothiazide may increase the excretion rate of Chromium which could result in a lower serum level and potentially a reduction in efficacy.
DB11145
Methyclothiazide may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.
DB11156
Methyclothiazide may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.
DB11164
Methyclothiazide may increase the excretion rate of Bicisate which could result in a lower serum level and potentially a reduction in efficacy.
DB11251
Methyclothiazide may increase the excretion rate of Tocopherol which could result in a lower serum level and potentially a reduction in efficacy.
DB11278
Methyclothiazide may increase the excretion rate of DL-Methylephedrine which could result in a lower serum level and potentially a reduction in efficacy.
DB11328
Methyclothiazide may increase the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a lower serum level and potentially a reduction in efficacy.
DB11338
Methyclothiazide may increase the excretion rate of Clove oil which could result in a lower serum level and potentially a reduction in efficacy.
DB11358
Methyclothiazide may increase the excretion rate of Evening primrose oil which could result in a lower serum level and potentially a reduction in efficacy.
DB11364
Methyclothiazide may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.
DB11367
Methyclothiazide may increase the excretion rate of Cefroxadine which could result in a lower serum level and potentially a reduction in efficacy.
DB11577
Methyclothiazide may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB11598
Methyclothiazide may increase the excretion rate of Antithrombin III human which could result in a lower serum level and potentially a reduction in efficacy.
DB11642
Methyclothiazide may increase the excretion rate of Pitolisant which could result in a lower serum level and potentially a reduction in efficacy.
DB11691
Methyclothiazide may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.
DB11699
Methyclothiazide may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.
DB11817
Methyclothiazide may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.
DB11901
Methyclothiazide may increase the excretion rate of Apalutamide which could result in a lower serum level and potentially a reduction in efficacy.
DB11915
Methyclothiazide may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.
DB11943
Methyclothiazide may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.
DB11989
Methyclothiazide may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.
DB12007
Methyclothiazide may increase the excretion rate of Isoflavone which could result in a lower serum level and potentially a reduction in efficacy.
DB12107
Methyclothiazide may increase the excretion rate of Vaborbactam which could result in a lower serum level and potentially a reduction in efficacy.
DB12151
Methyclothiazide may increase the excretion rate of Brincidofovir which could result in a lower serum level and potentially a reduction in efficacy.
DB12161
Methyclothiazide may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.
DB12615
Methyclothiazide may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.
DB12783
Methyclothiazide may increase the excretion rate of Benserazide which could result in a lower serum level and potentially a reduction in efficacy.
DB13025
Methyclothiazide may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.
DB13145
Methyclothiazide may increase the excretion rate of Nedaplatin which could result in a lower serum level and potentially a reduction in efficacy.
DB13156
Methyclothiazide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.
DB13178
Methyclothiazide may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.
DB13185
Methyclothiazide may increase the excretion rate of Oxabolone cipionate which could result in a lower serum level and potentially a reduction in efficacy.
DB13191
Methyclothiazide may increase the excretion rate of Phosphocreatine which could result in a lower serum level and potentially a reduction in efficacy.
DB13269
Methyclothiazide may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.
DB13293
Methyclothiazide may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.
DB13595
Methyclothiazide may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.
DB13873
Methyclothiazide may increase the excretion rate of Fenofibric acid which could result in a lower serum level and potentially a reduction in efficacy.
DB13884
Methyclothiazide may increase the excretion rate of Albutrepenonacog alfa which could result in a lower serum level and potentially a reduction in efficacy.
DB13909
Methyclothiazide may increase the excretion rate of Bismuth subgallate which could result in a lower serum level and potentially a reduction in efficacy.
DB13943
Methyclothiazide may increase the excretion rate of Testosterone cypionate which could result in a lower serum level and potentially a reduction in efficacy.
DB13944
Methyclothiazide may increase the excretion rate of Testosterone enanthate which could result in a lower serum level and potentially a reduction in efficacy.
DB13946
Methyclothiazide may increase the excretion rate of Testosterone undecanoate which could result in a lower serum level and potentially a reduction in efficacy.
DB13952
Methyclothiazide may increase the excretion rate of Estradiol acetate which could result in a lower serum level and potentially a reduction in efficacy.
DB13954
Methyclothiazide may increase the excretion rate of Estradiol cypionate which could result in a lower serum level and potentially a reduction in efficacy.
DB13955
Methyclothiazide may increase the excretion rate of Estradiol dienanthate which could result in a lower serum level and potentially a reduction in efficacy.
DB13956
Methyclothiazide may increase the excretion rate of Estradiol valerate which could result in a lower serum level and potentially a reduction in efficacy.
DB13967
Methyclothiazide may increase the excretion rate of Patent Blue which could result in a lower serum level and potentially a reduction in efficacy.
DB14006
Methyclothiazide may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy.
DB14007
Methyclothiazide may increase the excretion rate of Pentetic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB14126
Methyclothiazide may increase the excretion rate of Tenofovir which could result in a lower serum level and potentially a reduction in efficacy.
DB14526
Methyclothiazide may increase the excretion rate of Chromic citrate which could result in a lower serum level and potentially a reduction in efficacy.
DB14527
Methyclothiazide may increase the excretion rate of Chromic nitrate which could result in a lower serum level and potentially a reduction in efficacy.
DB14528
Methyclothiazide may increase the excretion rate of Chromium gluconate which could result in a lower serum level and potentially a reduction in efficacy.
DB14529
Methyclothiazide may increase the excretion rate of Chromium nicotinate which could result in a lower serum level and potentially a reduction in efficacy.
DB14530
Methyclothiazide may increase the excretion rate of Chromous sulfate which could result in a lower serum level and potentially a reduction in efficacy.
DB14754
Methyclothiazide may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.
DB01438
Methyclothiazide may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.
DB06815
Methyclothiazide may increase the excretion rate of Pyrithione which could result in a lower serum level and potentially a reduction in efficacy.
DB11121
Methyclothiazide may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.
DB11085
Methyclothiazide may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.
DB11090
Methyclothiazide may increase the excretion rate of Potassium nitrate which could result in a lower serum level and potentially a reduction in efficacy.
DB14498
Methyclothiazide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.
DB15593
Methyclothiazide may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.
DB13987
Methyclothiazide may increase the excretion rate of Strontium chloride which could result in a lower serum level and potentially a reduction in efficacy.
DB01345
Methyclothiazide may increase the excretion rate of Potassium cation which could result in a lower serum level and potentially a reduction in efficacy.
DB04890
Methyclothiazide may increase the excretion rate of Bepotastine which could result in a lower serum level and potentially a reduction in efficacy.
DB01356
Methyclothiazide may increase the excretion rate of Lithium cation which could result in a lower serum level and potentially a reduction in efficacy.
DB04930
Methyclothiazide may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.
DB00008
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2a.
DB00011
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-n1.
DB00018
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-n3.
DB00022
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2b.
DB00033
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon gamma-1b.
DB00034
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2a, Recombinant.
DB00056
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Gemtuzumab ozogamicin.
DB00068
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon beta-1b.
DB00069
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfacon-1.
DB00073
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Rituximab.
DB00078
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibritumomab tiuxetan.
DB00087
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Alemtuzumab.
DB00105
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2b.
DB00120
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Phenylalanine.
DB00242
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cladribine.
DB00276
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Amsacrine.
DB00291
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Chlorambucil.
DB00293
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Raltitrexed.
DB00305
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mitomycin.
DB00307
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bexarotene.
DB00309
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vindesine.
DB00352
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tioguanine.
DB00361
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vinorelbine.
DB00428
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Streptozocin.
DB00444
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Teniposide.
DB00445
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Epirubicin.
DB00446
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Chloramphenicol.
DB00488
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Altretamine.
DB00495
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Zidovudine.
DB00526
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Oxaliplatin.
DB00544
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Fluorouracil.
DB00550
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Propylthiouracil.
DB00570
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vinblastine.
DB00619
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Imatinib.
DB00694
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Daunorubicin.
DB00762
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Irinotecan.
DB00773
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Etoposide.
DB00859
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Penicillamine.
DB00864
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tacrolimus.
DB00877
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Sirolimus.
DB00888
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mechlorethamine.
DB00970
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Dactinomycin.
DB00987
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cytarabine.
DB00997
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Doxorubicin.
DB01005
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Hydroxyurea.
DB01008
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Busulfan.
DB01033
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mercaptopurine.
DB01042
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Melphalan.
DB01073
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Fludarabine.
DB01177
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Idarubicin.
DB01204
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Mitoxantrone.
DB01206
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Lomustine.
DB01248
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Docetaxel.
DB01254
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Dasatinib.
DB01262
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Decitabine.
DB01280
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Nelarabine.
DB01590
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Everolimus.
DB02546
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Vorinostat.
DB04572
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Thiotepa.
DB04845
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ixabepilone.
DB04868
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Nilotinib.
DB05015
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Belinostat.
DB05109
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Trabectedin.
DB05258
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa.
DB05472
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Human interferon omega-1.
DB05773
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Trastuzumab emtansine.
DB06287
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Temsirolimus.
DB06616
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bosutinib.
DB06769
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bendamustine.
DB06772
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cabazitaxel.
DB08871
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Eribulin.
DB08889
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Carfilzomib.
DB08895
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tofacitinib.
DB08901
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ponatinib.
DB09042
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tedizolid phosphate.
DB09052
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Blinatumomab.
DB09053
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibrutinib.
DB09073
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Palbociclib.
DB09074
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Olaparib.
DB09122
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon beta-1a.
DB12814
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Cepeginterferon alfa-2B.
DB00188
The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Bortezomib.
DB00368
The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Methyclothiazide.
DB00668
The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Methyclothiazide.
DB06262
The risk or severity of Cardiac Arrhythmia can be increased when Droxidopa is combined with Methyclothiazide.
DB06707
The risk or severity of Cardiac Arrhythmia can be increased when Levonordefrin is combined with Methyclothiazide.
DB06814
The risk or severity of Cardiac Arrhythmia can be increased when Protokylol is combined with Methyclothiazide.
DB11124
The risk or severity of Cardiac Arrhythmia can be increased when Racepinephrine is combined with Methyclothiazide.
DB12927
The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Methyclothiazide.
DB13917
The risk or severity of Cardiac Arrhythmia can be increased when Deoxyepinephrine is combined with Methyclothiazide.
DB01364
The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Methyclothiazide.
DB00331
The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.
DB00193
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tramadol.
DB00295
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Morphine.
DB00318
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Codeine.
DB00327
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Hydromorphone.
DB00333
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Methadone.
DB00454
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meperidine.
DB00497
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxycodone.
DB00611
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Butorphanol.
DB00647
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dextropropoxyphene.
DB00652
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pentazocine.
DB00704
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naltrexone.
DB00708
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sufentanil.
DB00802
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alfentanil.
DB00813
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fentanyl.
DB00844
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nalbuphine.
DB00854
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Levorphanol.
DB00899
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Remifentanil.
DB00921
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Buprenorphine.
DB00956
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Hydrocodone.
DB01081
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diphenoxylate.
DB01192
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxymorphone.
DB01209
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dezocine.
DB01227
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Levacetylmethadol.
DB01433
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Methadyl acetate.
DB01450
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dihydroetorphine.
DB01452
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diamorphine.
DB01459
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bezitramide.
DB01466
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ethylmorphine.
DB01497
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etorphine.
DB01529
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dextromoramide.
DB01531
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Desomorphine.
DB01535
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carfentanil.
DB01551
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dihydrocodeine.
DB01555
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alphacetylmethadol.
DB01565
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dihydromorphine.
DB06204
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tapentadol.
DB06738
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketobemidone.
DB08861
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with DPDPE.
DB09174
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lofentanil.
DB09272
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Eluxadoline.
DB11130
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Opium.
DB11609
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Normethadone.
DB12492
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piritramide.
DB13160
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alphaprodine.
DB13454
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nicomorphine.
DB13478
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meptazinol.
DB13605
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenoperidine.
DB13606
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenazocine.
DB13787
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tilidine.
DB15360
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carfentanil, C-11.
DB15465
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benzhydrocodone.
DB00945
Acetylsalicylic acid may decrease the excretion rate of Methyclothiazide which could result in a higher serum level.
DB00814
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.
DB14513
The serum concentration of Magnesium can be decreased when it is combined with Methyclothiazide.
DB00001
The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methyclothiazide.
DB00006
The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Methyclothiazide.
DB00009
The therapeutic efficacy of Alteplase can be decreased when used in combination with Methyclothiazide.
DB00013
The therapeutic efficacy of Urokinase can be decreased when used in combination with Methyclothiazide.
DB00015
The therapeutic efficacy of Reteplase can be decreased when used in combination with Methyclothiazide.
DB00029
The therapeutic efficacy of Anistreplase can be decreased when used in combination with Methyclothiazide.
DB00031
The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Methyclothiazide.
DB00054
The therapeutic efficacy of Abciximab can be decreased when used in combination with Methyclothiazide.
DB00055
The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Methyclothiazide.
DB00266
The therapeutic efficacy of Dicoumarol can be decreased when used in combination with Methyclothiazide.
DB00278
The therapeutic efficacy of Argatroban can be decreased when used in combination with Methyclothiazide.
DB00407
The therapeutic efficacy of Ardeparin can be decreased when used in combination with Methyclothiazide.
DB00498
The therapeutic efficacy of Phenindione can be decreased when used in combination with Methyclothiazide.
DB00686
The therapeutic efficacy of Pentosan polysulfate can be decreased when used in combination with Methyclothiazide.
DB00946
The therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Methyclothiazide.
DB00974
The therapeutic efficacy of Edetic acid can be decreased when used in combination with Methyclothiazide.
DB01109
The therapeutic efficacy of Heparin can be decreased when used in combination with Methyclothiazide.
DB01225
The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Methyclothiazide.
DB01418
The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Methyclothiazide.
DB03410
The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Methyclothiazide.
DB04665
The therapeutic efficacy of Coumarin can be decreased when used in combination with Methyclothiazide.
DB04898
The therapeutic efficacy of Ximelagatran can be decreased when used in combination with Methyclothiazide.
DB04925
The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Methyclothiazide.
DB04932
The therapeutic efficacy of Defibrotide can be decreased when used in combination with Methyclothiazide.
DB05099
The therapeutic efficacy of Ancrod can be decreased when used in combination with Methyclothiazide.
DB05229
The therapeutic efficacy of Beraprost can be decreased when used in combination with Methyclothiazide.
DB05254
The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Methyclothiazide.
DB06271
The therapeutic efficacy of Sulodexide can be decreased when used in combination with Methyclothiazide.
DB06294
The therapeutic efficacy of Semuloparin can be decreased when used in combination with Methyclothiazide.
DB06406
The therapeutic efficacy of Idraparinux can be decreased when used in combination with Methyclothiazide.
DB06441
The therapeutic efficacy of Cangrelor can be decreased when used in combination with Methyclothiazide.
DB06543
The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Methyclothiazide.
DB06605
The therapeutic efficacy of Apixaban can be decreased when used in combination with Methyclothiazide.
DB06635
The therapeutic efficacy of Otamixaban can be decreased when used in combination with Methyclothiazide.
DB06679
The therapeutic efficacy of Amediplase can be decreased when used in combination with Methyclothiazide.
DB06754
The therapeutic efficacy of Danaparoid can be decreased when used in combination with Methyclothiazide.
DB06779
The therapeutic efficacy of Dalteparin can be decreased when used in combination with Methyclothiazide.
DB06822
The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Methyclothiazide.
DB08496
The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Methyclothiazide.
DB08794
The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Methyclothiazide.
DB08813
The therapeutic efficacy of Nadroparin can be decreased when used in combination with Methyclothiazide.
DB08814
The therapeutic efficacy of Triflusal can be decreased when used in combination with Methyclothiazide.
DB08816
The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Methyclothiazide.
DB08994
The therapeutic efficacy of Ditazole can be decreased when used in combination with Methyclothiazide.
DB09030
The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Methyclothiazide.
DB09125
The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Methyclothiazide.
DB09154
The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Methyclothiazide.
DB09258
The therapeutic efficacy of Bemiparin can be decreased when used in combination with Methyclothiazide.
DB09260
The therapeutic efficacy of Parnaparin can be decreased when used in combination with Methyclothiazide.
DB11095
The therapeutic efficacy of Desirudin can be decreased when used in combination with Methyclothiazide.
DB11154
The therapeutic efficacy of Zinc citrate can be decreased when used in combination with Methyclothiazide.
DB11166
The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Methyclothiazide.
DB11268
The therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Methyclothiazide.
DB11312
The therapeutic efficacy of Protein C can be decreased when used in combination with Methyclothiazide.
DB11984
The therapeutic efficacy of Letaxaban can be decreased when used in combination with Methyclothiazide.
DB12289
The therapeutic efficacy of Darexaban can be decreased when used in combination with Methyclothiazide.
DB12364
The therapeutic efficacy of Betrixaban can be decreased when used in combination with Methyclothiazide.
DB12598
The therapeutic efficacy of Nafamostat can be decreased when used in combination with Methyclothiazide.
DB12726
The therapeutic efficacy of Monteplase can be decreased when used in combination with Methyclothiazide.
DB12831
The therapeutic efficacy of Gabexate can be decreased when used in combination with Methyclothiazide.
DB13124
The therapeutic efficacy of Troxerutin can be decreased when used in combination with Methyclothiazide.
DB13136
The therapeutic efficacy of Fluindione can be decreased when used in combination with Methyclothiazide.
DB13149
The therapeutic efficacy of Protein S human can be decreased when used in combination with Methyclothiazide.
DB13199
The therapeutic efficacy of Brinase can be decreased when used in combination with Methyclothiazide.
DB13275
The therapeutic efficacy of Clorindione can be decreased when used in combination with Methyclothiazide.
DB13347
The therapeutic efficacy of Diphenadione can be decreased when used in combination with Methyclothiazide.
DB13451
The therapeutic efficacy of Tioclomarol can be decreased when used in combination with Methyclothiazide.
DB13616
The therapeutic efficacy of Melagatran can be decreased when used in combination with Methyclothiazide.
DB13646
The therapeutic efficacy of Saruplase can be decreased when used in combination with Methyclothiazide.
DB14055
The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Methyclothiazide.
DB14598
The therapeutic efficacy of Edetate calcium disodium anhydrous can be decreased when used in combination with Methyclothiazide.
DB14726
The therapeutic efficacy of Dabigatran can be decreased when used in combination with Methyclothiazide.
DB09259
The therapeutic efficacy of Reviparin can be decreased when used in combination with Methyclothiazide.
DB00788
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.
DB06737
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen.
DB07402
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.
DB13514
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pranoprofen.
DB04831
The therapeutic efficacy of Tienilic acid can be decreased when used in combination with Methyclothiazide.
DB01032
The therapeutic efficacy of Probenecid can be decreased when used in combination with Methyclothiazide.
DB11560
The therapeutic efficacy of Lesinurad can be decreased when used in combination with Methyclothiazide.
DB01394
The therapeutic efficacy of Colchicine can be decreased when used in combination with Methyclothiazide.
DB00328
The therapeutic efficacy of Indomethacin can be decreased when used in combination with Methyclothiazide.
DB00049
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Methyclothiazide.
DB01138
The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Methyclothiazide.
DB04854
The therapeutic efficacy of Febuxostat can be decreased when used in combination with Methyclothiazide.
DB09208
The therapeutic efficacy of Pegloticase can be decreased when used in combination with Methyclothiazide.
DB11873
The therapeutic efficacy of Verinurad can be decreased when used in combination with Methyclothiazide.
DB12319
The therapeutic efficacy of Benzbromarone can be decreased when used in combination with Methyclothiazide.
DB13277
The therapeutic efficacy of Benziodarone can be decreased when used in combination with Methyclothiazide.
DB13545
The therapeutic efficacy of Isobromindione can be decreased when used in combination with Methyclothiazide.
DB13551
The therapeutic efficacy of Cinchophen can be decreased when used in combination with Methyclothiazide.
DB13807
The therapeutic efficacy of Tisopurine can be decreased when used in combination with Methyclothiazide.
DB00177
The therapeutic efficacy of Valsartan can be increased when used in combination with Methyclothiazide.
DB00275
The therapeutic efficacy of Olmesartan can be increased when used in combination with Methyclothiazide.
DB00678
The therapeutic efficacy of Losartan can be increased when used in combination with Methyclothiazide.
DB00796
The therapeutic efficacy of Candesartan cilexetil can be increased when used in combination with Methyclothiazide.
DB00876
The therapeutic efficacy of Eprosartan can be increased when used in combination with Methyclothiazide.
DB00966
The therapeutic efficacy of Telmisartan can be increased when used in combination with Methyclothiazide.
DB01029
The therapeutic efficacy of Irbesartan can be increased when used in combination with Methyclothiazide.
DB01347
The therapeutic efficacy of Saprisartan can be increased when used in combination with Methyclothiazide.
DB13919
The therapeutic efficacy of Candesartan can be increased when used in combination with Methyclothiazide.
DB00657
The therapeutic efficacy of Mecamylamine can be increased when used in combination with Methyclothiazide.
DB01090
The therapeutic efficacy of Pentolinium can be increased when used in combination with Methyclothiazide.
DB01116
The therapeutic efficacy of Trimethaphan can be increased when used in combination with Methyclothiazide.
DB08960
The therapeutic efficacy of Hexamethonium can be increased when used in combination with Methyclothiazide.
DB00178
The therapeutic efficacy of Ramipril can be increased when used in combination with Methyclothiazide.
DB00492
The therapeutic efficacy of Fosinopril can be increased when used in combination with Methyclothiazide.
DB00519
The therapeutic efficacy of Trandolapril can be increased when used in combination with Methyclothiazide.
DB00542
The therapeutic efficacy of Benazepril can be increased when used in combination with Methyclothiazide.
DB00584
The therapeutic efficacy of Enalapril can be increased when used in combination with Methyclothiazide.
DB00691
The therapeutic efficacy of Moexipril can be increased when used in combination with Methyclothiazide.
DB00722
The therapeutic efficacy of Lisinopril can be increased when used in combination with Methyclothiazide.
DB00790
The therapeutic efficacy of Perindopril can be increased when used in combination with Methyclothiazide.
DB00881
The therapeutic efficacy of Quinapril can be increased when used in combination with Methyclothiazide.
DB00886
The therapeutic efficacy of Omapatrilat can be increased when used in combination with Methyclothiazide.
DB01180
The therapeutic efficacy of Rescinnamine can be increased when used in combination with Methyclothiazide.
DB01197
The therapeutic efficacy of Captopril can be increased when used in combination with Methyclothiazide.
DB01340
The therapeutic efficacy of Cilazapril can be increased when used in combination with Methyclothiazide.
DB01348
The therapeutic efficacy of Spirapril can be increased when used in combination with Methyclothiazide.
DB08836
The therapeutic efficacy of Temocapril can be increased when used in combination with Methyclothiazide.
DB09477
The therapeutic efficacy of Enalaprilat can be increased when used in combination with Methyclothiazide.
DB11783
The therapeutic efficacy of Imidapril can be increased when used in combination with Methyclothiazide.
DB13166
The therapeutic efficacy of Zofenopril can be increased when used in combination with Methyclothiazide.
DB13312
The therapeutic efficacy of Delapril can be increased when used in combination with Methyclothiazide.
DB14125
The therapeutic efficacy of Benazeprilat can be increased when used in combination with Methyclothiazide.
DB14207
The therapeutic efficacy of Fosinoprilat can be increased when used in combination with Methyclothiazide.
DB14208
The therapeutic efficacy of Ramiprilat can be increased when used in combination with Methyclothiazide.
DB14213
The therapeutic efficacy of Perindoprilat can be increased when used in combination with Methyclothiazide.
DB14217
The therapeutic efficacy of Quinaprilat can be increased when used in combination with Methyclothiazide.
DB01626
The therapeutic efficacy of Methyclothiazide can be increased when used in combination with Pargyline.
DB00695
The therapeutic efficacy of Furosemide can be increased when used in combination with Methyclothiazide.
DB00187
The therapeutic efficacy of Esmolol can be increased when used in combination with Methyclothiazide.
DB00195
The therapeutic efficacy of Betaxolol can be increased when used in combination with Methyclothiazide.
DB00206
The therapeutic efficacy of Reserpine can be increased when used in combination with Methyclothiazide.
DB00212
The therapeutic efficacy of Remikiren can be increased when used in combination with Methyclothiazide.
DB00214
The therapeutic efficacy of Torasemide can be increased when used in combination with Methyclothiazide.
DB00217
The therapeutic efficacy of Bethanidine can be increased when used in combination with Methyclothiazide.
DB00226
The therapeutic efficacy of Guanadrel can be increased when used in combination with Methyclothiazide.
DB00264
The therapeutic efficacy of Metoprolol can be increased when used in combination with Methyclothiazide.
DB00270
The therapeutic efficacy of Isradipine can be increased when used in combination with Methyclothiazide.
DB00310
The therapeutic efficacy of Chlorthalidone can be increased when used in combination with Methyclothiazide.
DB00325
The therapeutic efficacy of Nitroprusside can be increased when used in combination with Methyclothiazide.
DB00335
The therapeutic efficacy of Atenolol can be increased when used in combination with Methyclothiazide.
DB00343
The therapeutic efficacy of Diltiazem can be increased when used in combination with Methyclothiazide.
DB00350
The therapeutic efficacy of Minoxidil can be increased when used in combination with Methyclothiazide.
DB00373
The therapeutic efficacy of Timolol can be increased when used in combination with Methyclothiazide.
DB00374
The therapeutic efficacy of Treprostinil can be increased when used in combination with Methyclothiazide.
DB00381
The therapeutic efficacy of Amlodipine can be increased when used in combination with Methyclothiazide.
DB00393
The therapeutic efficacy of Nimodipine can be increased when used in combination with Methyclothiazide.
DB00401
The therapeutic efficacy of Nisoldipine can be increased when used in combination with Methyclothiazide.
DB00436
The therapeutic efficacy of Bendroflumethiazide can be increased when used in combination with Methyclothiazide.
DB00457
The therapeutic efficacy of Prazosin can be increased when used in combination with Methyclothiazide.
DB00524
The therapeutic efficacy of Metolazone can be increased when used in combination with Methyclothiazide.
DB00528
The therapeutic efficacy of Lercanidipine can be increased when used in combination with Methyclothiazide.
DB00559
The therapeutic efficacy of Bosentan can be increased when used in combination with Methyclothiazide.
DB00571
The therapeutic efficacy of Propranolol can be increased when used in combination with Methyclothiazide.
DB00575
The therapeutic efficacy of Clonidine can be increased when used in combination with Methyclothiazide.
DB00590
The therapeutic efficacy of Doxazosin can be increased when used in combination with Methyclothiazide.
DB00598
The therapeutic efficacy of Labetalol can be increased when used in combination with Methyclothiazide.
DB00606
The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Methyclothiazide.
DB00612
The therapeutic efficacy of Bisoprolol can be increased when used in combination with Methyclothiazide.
DB00616
The therapeutic efficacy of Candoxatril can be increased when used in combination with Methyclothiazide.
DB00622
The therapeutic efficacy of Nicardipine can be increased when used in combination with Methyclothiazide.
DB00629
The therapeutic efficacy of Guanabenz can be increased when used in combination with Methyclothiazide.
DB00692
The therapeutic efficacy of Phentolamine can be increased when used in combination with Methyclothiazide.
DB00700
The therapeutic efficacy of Eplerenone can be increased when used in combination with Methyclothiazide.
DB00727
The therapeutic efficacy of Nitroglycerin can be increased when used in combination with Methyclothiazide.
DB00765
The therapeutic efficacy of Metyrosine can be increased when used in combination with Methyclothiazide.
DB00774
The therapeutic efficacy of Hydroflumethiazide can be increased when used in combination with Methyclothiazide.
DB00785
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Methyclothiazide.
DB00797
The therapeutic efficacy of Tolazoline can be increased when used in combination with Methyclothiazide.
DB00800
The therapeutic efficacy of Fenoldopam can be increased when used in combination with Methyclothiazide.
DB00808
The therapeutic efficacy of Indapamide can be increased when used in combination with Methyclothiazide.
DB00820
The therapeutic efficacy of Tadalafil can be increased when used in combination with Methyclothiazide.
DB00866
The therapeutic efficacy of Alprenolol can be increased when used in combination with Methyclothiazide.
DB00880
The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Methyclothiazide.
DB00925
The therapeutic efficacy of Phenoxybenzamine can be increased when used in combination with Methyclothiazide.
DB00960
The therapeutic efficacy of Pindolol can be increased when used in combination with Methyclothiazide.
DB00968
The therapeutic efficacy of Methyldopa can be increased when used in combination with Methyclothiazide.
DB00999
The therapeutic efficacy of Hydrochlorothiazide can be increased when used in combination with Methyclothiazide.
DB01018
The therapeutic efficacy of Guanfacine can be increased when used in combination with Methyclothiazide.
DB01021
The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Methyclothiazide.
DB01023
The therapeutic efficacy of Felodipine can be increased when used in combination with Methyclothiazide.
DB01054
The therapeutic efficacy of Nitrendipine can be increased when used in combination with Methyclothiazide.
DB01136
The therapeutic efficacy of Carvedilol can be increased when used in combination with Methyclothiazide.
DB01158
The therapeutic efficacy of Bretylium can be increased when used in combination with Methyclothiazide.
DB01162
The therapeutic efficacy of Terazosin can be increased when used in combination with Methyclothiazide.
DB01170
The therapeutic efficacy of Guanethidine can be increased when used in combination with Methyclothiazide.
DB01193
The therapeutic efficacy of Acebutolol can be increased when used in combination with Methyclothiazide.
DB01203
The therapeutic efficacy of Nadolol can be increased when used in combination with Methyclothiazide.
DB01240
The therapeutic efficacy of Epoprostenol can be increased when used in combination with Methyclothiazide.
DB01244
The therapeutic efficacy of Bepridil can be increased when used in combination with Methyclothiazide.
DB01275
The therapeutic efficacy of Hydralazine can be increased when used in combination with Methyclothiazide.
DB01295
The therapeutic efficacy of Bevantolol can be increased when used in combination with Methyclothiazide.
DB01297
The therapeutic efficacy of Practolol can be increased when used in combination with Methyclothiazide.
DB01324
The therapeutic efficacy of Polythiazide can be increased when used in combination with Methyclothiazide.
DB01359
The therapeutic efficacy of Penbutolol can be increased when used in combination with Methyclothiazide.
DB01388
The therapeutic efficacy of Mibefradil can be increased when used in combination with Methyclothiazide.
DB01580
The therapeutic efficacy of Oxprenolol can be increased when used in combination with Methyclothiazide.
DB03322
The therapeutic efficacy of Dexpropranolol can be increased when used in combination with Methyclothiazide.
DB04840
The therapeutic efficacy of Debrisoquine can be increased when used in combination with Methyclothiazide.
DB04846
The therapeutic efficacy of Celiprolol can be increased when used in combination with Methyclothiazide.
DB04861
The therapeutic efficacy of Nebivolol can be increased when used in combination with Methyclothiazide.
DB04948
The therapeutic efficacy of Lofexidine can be increased when used in combination with Methyclothiazide.
DB06268
The therapeutic efficacy of Sitaxentan can be increased when used in combination with Methyclothiazide.
DB06403
The therapeutic efficacy of Ambrisentan can be increased when used in combination with Methyclothiazide.
DB06445
The therapeutic efficacy of Diethylnorspermine can be increased when used in combination with Methyclothiazide.
DB06712
The therapeutic efficacy of Nilvadipine can be increased when used in combination with Methyclothiazide.
DB06762
The therapeutic efficacy of Pinacidil can be increased when used in combination with Methyclothiazide.
DB07767
The therapeutic efficacy of Ferulic acid can be increased when used in combination with Methyclothiazide.
DB08808
The therapeutic efficacy of Bupranolol can be increased when used in combination with Methyclothiazide.
DB08931
The therapeutic efficacy of Riociguat can be increased when used in combination with Methyclothiazide.
DB08932
The therapeutic efficacy of Macitentan can be increased when used in combination with Methyclothiazide.
DB08950
The therapeutic efficacy of Indoramin can be increased when used in combination with Methyclothiazide.
DB08952
The therapeutic efficacy of Indenolol can be increased when used in combination with Methyclothiazide.
DB09026
The therapeutic efficacy of Aliskiren can be increased when used in combination with Methyclothiazide.
DB09206
The therapeutic efficacy of Trimazosin can be increased when used in combination with Methyclothiazide.
DB09235
The therapeutic efficacy of Efonidipine can be increased when used in combination with Methyclothiazide.
DB09238
The therapeutic efficacy of Manidipine can be increased when used in combination with Methyclothiazide.
DB09239
The therapeutic efficacy of Niguldipine can be increased when used in combination with Methyclothiazide.
DB09242
The therapeutic efficacy of Moxonidine can be increased when used in combination with Methyclothiazide.
DB09363
The therapeutic efficacy of Rauwolfia serpentina root can be increased when used in combination with Methyclothiazide.
DB11362
The therapeutic efficacy of Selexipag can be increased when used in combination with Methyclothiazide.
DB11720
The therapeutic efficacy of Angiotensin 1-7 can be increased when used in combination with Methyclothiazide.
DB11738
The therapeutic efficacy of Rilmenidine can be increased when used in combination with Methyclothiazide.
DB11770
The therapeutic efficacy of Talinolol can be increased when used in combination with Methyclothiazide.
DB12054
The therapeutic efficacy of BQ-123 can be increased when used in combination with Methyclothiazide.
DB12092
The therapeutic efficacy of Naftopidil can be increased when used in combination with Methyclothiazide.
DB12093
The therapeutic efficacy of Tetrahydropalmatine can be increased when used in combination with Methyclothiazide.
DB12212
The therapeutic efficacy of Landiolol can be increased when used in combination with Methyclothiazide.
DB12465
The therapeutic efficacy of Ketanserin can be increased when used in combination with Methyclothiazide.
DB12661
The therapeutic efficacy of Urapidil can be increased when used in combination with Methyclothiazide.
DB12766
The therapeutic efficacy of Cicletanine can be increased when used in combination with Methyclothiazide.
DB12945
The therapeutic efficacy of Dihydralazine can be increased when used in combination with Methyclothiazide.
DB13211
The therapeutic efficacy of Guanoxan can be increased when used in combination with Methyclothiazide.
DB13374
The therapeutic efficacy of Vincamine can be increased when used in combination with Methyclothiazide.
DB13400
The therapeutic efficacy of Linsidomine can be increased when used in combination with Methyclothiazide.
DB13410
The therapeutic efficacy of Guanoxabenz can be increased when used in combination with Methyclothiazide.
DB13429
The therapeutic efficacy of Tolonidine can be increased when used in combination with Methyclothiazide.
DB13435
The therapeutic efficacy of Endralazine can be increased when used in combination with Methyclothiazide.
DB13443
The therapeutic efficacy of Esatenolol can be increased when used in combination with Methyclothiazide.
DB13452
The therapeutic efficacy of Cadralazine can be increased when used in combination with Methyclothiazide.
DB13508
The therapeutic efficacy of Cloranolol can be increased when used in combination with Methyclothiazide.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Methyclothiazide.
DB13575
The therapeutic efficacy of Bietaserpine can be increased when used in combination with Methyclothiazide.
DB13604
The therapeutic efficacy of Guanazodine can be increased when used in combination with Methyclothiazide.
DB13631
The therapeutic efficacy of Methoserpidine can be increased when used in combination with Methyclothiazide.
DB13757
The therapeutic efficacy of Epanolol can be increased when used in combination with Methyclothiazide.
DB13779
The therapeutic efficacy of Guanoclor can be increased when used in combination with Methyclothiazide.
DB13801
The therapeutic efficacy of Muzolimine can be increased when used in combination with Methyclothiazide.
DB13803
The therapeutic efficacy of Xipamide can be increased when used in combination with Methyclothiazide.
DB14068
The therapeutic efficacy of Dexniguldipine can be increased when used in combination with Methyclothiazide.
DB14094
The therapeutic efficacy of Tocopherylquinone can be increased when used in combination with Methyclothiazide.
DB00287
The therapeutic efficacy of Travoprost can be increased when used in combination with Methyclothiazide.
DB00521
The therapeutic efficacy of Carteolol can be increased when used in combination with Methyclothiazide.
DB00869
The therapeutic efficacy of Dorzolamide can be increased when used in combination with Methyclothiazide.
DB00905
The therapeutic efficacy of Bimatoprost can be increased when used in combination with Methyclothiazide.
DB01214
The therapeutic efficacy of Metipranolol can be increased when used in combination with Methyclothiazide.
DB06826
The therapeutic efficacy of Unoprostone can be increased when used in combination with Methyclothiazide.
DB09237
The therapeutic efficacy of Levamlodipine can be increased when used in combination with Methyclothiazide.
DB00681
The risk or severity of electrolyte imbalance can be increased when Methyclothiazide is combined with Amphotericin B.
DB00180
The risk or severity of electrolyte imbalance can be increased when Flunisolide is combined with Methyclothiazide.
DB00394
The risk or severity of electrolyte imbalance can be increased when Beclomethasone dipropionate is combined with Methyclothiazide.
DB00443
The risk or severity of electrolyte imbalance can be increased when Betamethasone is combined with Methyclothiazide.
DB00588
The risk or severity of electrolyte imbalance can be increased when Fluticasone propionate is combined with Methyclothiazide.
DB00591
The risk or severity of electrolyte imbalance can be increased when Fluocinolone acetonide is combined with Methyclothiazide.
DB00620
The risk or severity of electrolyte imbalance can be increased when Triamcinolone is combined with Methyclothiazide.
DB00635
The risk or severity of electrolyte imbalance can be increased when Prednisone is combined with Methyclothiazide.
DB00687
The risk or severity of electrolyte imbalance can be increased when Fludrocortisone is combined with Methyclothiazide.
DB00741
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone is combined with Methyclothiazide.
DB00764
The risk or severity of electrolyte imbalance can be increased when Mometasone is combined with Methyclothiazide.
DB00860
The risk or severity of electrolyte imbalance can be increased when Prednisolone is combined with Methyclothiazide.
DB00959
The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Methyclothiazide.
DB01108
The risk or severity of electrolyte imbalance can be increased when Trilostane is combined with Methyclothiazide.
DB01222
The risk or severity of electrolyte imbalance can be increased when Budesonide is combined with Methyclothiazide.
DB01234
The risk or severity of electrolyte imbalance can be increased when Dexamethasone is combined with Methyclothiazide.
DB01285
The risk or severity of electrolyte imbalance can be increased when Corticotropin is combined with Methyclothiazide.
DB01380
The risk or severity of electrolyte imbalance can be increased when Cortisone acetate is combined with Methyclothiazide.
DB01384
The risk or severity of electrolyte imbalance can be increased when Paramethasone is combined with Methyclothiazide.
DB01410
The risk or severity of electrolyte imbalance can be increased when Ciclesonide is combined with Methyclothiazide.
DB04630
The risk or severity of electrolyte imbalance can be increased when Aldosterone is combined with Methyclothiazide.
DB08906
The risk or severity of electrolyte imbalance can be increased when Fluticasone furoate is combined with Methyclothiazide.
DB08970
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Methyclothiazide.
DB08971
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Methyclothiazide.
DB09091
The risk or severity of electrolyte imbalance can be increased when Tixocortol is combined with Methyclothiazide.
DB09378
The risk or severity of electrolyte imbalance can be increased when Fluprednisolone is combined with Methyclothiazide.
DB09383
The risk or severity of electrolyte imbalance can be increased when Meprednisone is combined with Methyclothiazide.
DB11487
The risk or severity of electrolyte imbalance can be increased when Dexamethasone isonicotinate is combined with Methyclothiazide.
DB11529
The risk or severity of electrolyte imbalance can be increased when Melengestrol is combined with Methyclothiazide.
DB11750
The risk or severity of electrolyte imbalance can be increased when Clobetasol is combined with Methyclothiazide.
DB11921
The risk or severity of electrolyte imbalance can be increased when Deflazacort is combined with Methyclothiazide.
DB13003
The risk or severity of electrolyte imbalance can be increased when Cortivazol is combined with Methyclothiazide.
DB13208
The risk or severity of electrolyte imbalance can be increased when Prednylidene is combined with Methyclothiazide.
DB13223
The risk or severity of electrolyte imbalance can be increased when Fluocortin is combined with Methyclothiazide.
DB13491
The risk or severity of electrolyte imbalance can be increased when Fluperolone is combined with Methyclothiazide.
DB13664
The risk or severity of electrolyte imbalance can be increased when Formocortal is combined with Methyclothiazide.
DB13728
The risk or severity of electrolyte imbalance can be increased when Halometasone is combined with Methyclothiazide.
DB13843
The risk or severity of electrolyte imbalance can be increased when Cloprednol is combined with Methyclothiazide.
DB13856
The risk or severity of electrolyte imbalance can be increased when Fluclorolone is combined with Methyclothiazide.
DB13867
The risk or severity of electrolyte imbalance can be increased when Fluticasone is combined with Methyclothiazide.
DB14512
The risk or severity of electrolyte imbalance can be increased when Mometasone furoate is combined with Methyclothiazide.
DB14538
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone aceponate is combined with Methyclothiazide.
DB14539
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone acetate is combined with Methyclothiazide.
DB14541
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone cypionate is combined with Methyclothiazide.
DB14545
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone succinate is combined with Methyclothiazide.
DB00873
The risk or severity of electrolyte imbalance can be increased when Loteprednol is combined with Methyclothiazide.
DB14631
The risk or severity of electrolyte imbalance can be increased when Prednisolone phosphate is combined with Methyclothiazide.
DB14633
The risk or severity of electrolyte imbalance can be increased when Prednisolone hemisuccinate is combined with Methyclothiazide.
DB14634
The risk or severity of electrolyte imbalance can be increased when Fluprednidene acetate is combined with Methyclothiazide.
DB14643
The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Methyclothiazide.
DB14644
The risk or severity of electrolyte imbalance can be increased when Methylprednisolone hemisuccinate is combined with Methyclothiazide.
DB14646
The risk or severity of electrolyte imbalance can be increased when Prednisone acetate is combined with Methyclothiazide.
DB14652
The risk or severity of electrolyte imbalance can be increased when Clocortolone acetate is combined with Methyclothiazide.
DB14659
The risk or severity of electrolyte imbalance can be increased when Melengestrol acetate is combined with Methyclothiazide.
DB14669
The risk or severity of electrolyte imbalance can be increased when Betamethasone phosphate is combined with Methyclothiazide.
DB14681
The risk or severity of electrolyte imbalance can be increased when Cortisone is combined with Methyclothiazide.
DB00223
The risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Methyclothiazide.
DB00240
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Methyclothiazide.
DB00253
The risk or severity of electrolyte imbalance can be increased when Medrysone is combined with Methyclothiazide.
DB00288
The risk or severity of electrolyte imbalance can be increased when Amcinonide is combined with Methyclothiazide.
DB00324
The risk or severity of electrolyte imbalance can be increased when Fluorometholone is combined with Methyclothiazide.
DB00547
The risk or severity of electrolyte imbalance can be increased when Desoximetasone is combined with Methyclothiazide.
DB00596
The risk or severity of electrolyte imbalance can be increased when Ulobetasol is combined with Methyclothiazide.
DB00663
The risk or severity of electrolyte imbalance can be increased when Flumethasone is combined with Methyclothiazide.
DB00838
The risk or severity of electrolyte imbalance can be increased when Clocortolone is combined with Methyclothiazide.
DB00846
The risk or severity of electrolyte imbalance can be increased when Flurandrenolide is combined with Methyclothiazide.
DB00896
The risk or severity of electrolyte imbalance can be increased when Rimexolone is combined with Methyclothiazide.
DB01013
The risk or severity of electrolyte imbalance can be increased when Clobetasol propionate is combined with Methyclothiazide.
DB01047
The risk or severity of electrolyte imbalance can be increased when Fluocinonide is combined with Methyclothiazide.
DB01130
The risk or severity of electrolyte imbalance can be increased when Prednicarbate is combined with Methyclothiazide.
DB01260
The risk or severity of electrolyte imbalance can be increased when Desonide is combined with Methyclothiazide.
DB06781
The risk or severity of electrolyte imbalance can be increased when Difluprednate is combined with Methyclothiazide.
DB06786
The risk or severity of electrolyte imbalance can be increased when Halcinonide is combined with Methyclothiazide.
DB09095
The risk or severity of electrolyte imbalance can be increased when Difluocortolone is combined with Methyclothiazide.
DB13158
The risk or severity of electrolyte imbalance can be increased when Clobetasone is combined with Methyclothiazide.
DB14540
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone butyrate is combined with Methyclothiazide.
DB14543
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone probutate is combined with Methyclothiazide.
DB14544
The risk or severity of electrolyte imbalance can be increased when Hydrocortisone valerate is combined with Methyclothiazide.
DB15566
The risk or severity of electrolyte imbalance can be increased when Prednisolone acetate is combined with Methyclothiazide.
DB00390
Methyclothiazide may increase the hypokalemic activities of Digoxin.
DB00511
Methyclothiazide may increase the hypokalemic activities of Acetyldigitoxin.
DB01078
Methyclothiazide may increase the hypokalemic activities of Deslanoside.
DB01092
Methyclothiazide may increase the hypokalemic activities of Ouabain.
DB01396
Methyclothiazide may increase the hypokalemic activities of Digitoxin.
DB12843
Methyclothiazide may increase the hypokalemic activities of Oleandrin.
DB13240
Methyclothiazide may increase the hypokalemic activities of Cymarin.
DB13307
Methyclothiazide may increase the hypokalemic activities of Proscillaridin.
DB13401
Methyclothiazide may increase the hypokalemic activities of Metildigoxin.
DB13467
Methyclothiazide may increase the hypokalemic activities of Lanatoside C.
DB13537
Methyclothiazide may increase the hypokalemic activities of Gitoformate.
DB13691
Methyclothiazide may increase the hypokalemic activities of Acetyldigoxin.
DB13756
Methyclothiazide may increase the hypokalemic activities of Peruvoside.
DB06799
The therapeutic efficacy of Methenamine can be decreased when used in combination with Methyclothiazide.
DB01053
Methyclothiazide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.
DB06283
The risk or severity of CNS depression can be increased when Methyclothiazide is combined with Ziconotide.
DB09038
Methyclothiazide may increase the diuretic activities of Empagliflozin.
DB14881
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oliceridine.
DB00203
The risk or severity of hypotension can be increased when Sildenafil is combined with Methyclothiazide.
DB00862
The risk or severity of hypotension can be increased when Vardenafil is combined with Methyclothiazide.
DB05266
The risk or severity of hypotension can be increased when Ibudilast is combined with Methyclothiazide.
DB06237
The risk or severity of hypotension can be increased when Avanafil is combined with Methyclothiazide.
DB06267
The risk or severity of hypotension can be increased when Udenafil is combined with Methyclothiazide.
DB11792
The risk or severity of hypotension can be increased when Mirodenafil is combined with Methyclothiazide.
DB12010
The risk or severity of hypotension can be increased when Fostamatinib is combined with Methyclothiazide.

序列

实验性质

Water Solubility
11.2 mg/L

Melting Point
225 °C
PhysProp
logP
1.42
HANSCH,C ET AL. (1995)
pKa
9.4
MERCK INDEX (2001)

外部标识符

resource：Drugs Product Database (DPD)
identifier：10199
resource：ChEBI
identifier：6847
resource：PubChem Compound
identifier：4121
resource：PubChem Substance
identifier：46509197
resource：KEGG Compound
identifier：C07765
resource：KEGG Drug
identifier：D00656
resource：ChemSpider
identifier：3978
resource：PharmGKB
identifier：PA164748094
resource：Therapeutic Targets Database
identifier：DAP000746
resource：Wikipedia
identifier：Methyclothiazide
resource：ChEMBL
identifier：CHEMBL1577
resource：RxCUI
identifier：6860

外部链接

RxList
http://www.rxlist.com/cgi/generic3/methyclothiazide.htm
Drugs.com
http://www.drugs.com/cdi/methyclothiazide.html

路径

smpdb-id:SMP0000081
name:Methyclothiazide Action Pathway
category:drug_action
drugbank-id:DB00151
name:Cysteine
drugbank-id:DB00232
name:Methyclothiazide
drugbank-id:DB01345
name:Potassium cation
drugbank-id:DB03904
name:Urea
enzymes_uniprot-id:Q4U2R8
enzymes_uniprot-id:P55017
enzymes_uniprot-id:P05023
enzymes_uniprot-id:P50993
enzymes_uniprot-id:P13637
enzymes_uniprot-id:Q13733
enzymes_uniprot-id:P05026
enzymes_uniprot-id:P14415
enzymes_uniprot-id:P54709
enzymes_uniprot-id:B7ZKV8
enzymes_uniprot-id:P54710
enzymes_uniprot-id:P51800
enzymes_uniprot-id:P29972
enzymes_uniprot-id:Q13621
enzymes_uniprot-id:Q9UHW9
enzymes_uniprot-id:O15244
enzymes_uniprot-id:P41181
enzymes_uniprot-id:Q92482
enzymes_uniprot-id:P37088
enzymes_uniprot-id:P51168
enzymes_uniprot-id:P51172
enzymes_uniprot-id:P51170
enzymes_uniprot-id:P43005
enzymes_uniprot-id:Q9UHI5
enzymes_uniprot-id:P08195
enzymes_uniprot-id:Q01650
enzymes_uniprot-id:Q9NP91
enzymes_uniprot-id:Q969I6
enzymes_uniprot-id:Q9UM01
enzymes_uniprot-id:Q92536
enzymes_uniprot-id:P08235
enzymes_uniprot-id:Q07837
enzymes_uniprot-id:P82251
enzymes_uniprot-id:Q15849

目标

id:BE0000502
name:Solute carrier family 12 member 1
organism:Humans
action:inhibitor
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
known-action:yes
name:Solute carrier family 12 member 1
general-function:Sodium:potassium:chloride symporter activity
specific-function:Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
gene-name:SLC12A1
locus:15q15-q21.1
cellular-location:Membrane
transmembrane-regions:178-198 202-222 260-280 303-323 328-348 380-400 418-438 485-505 551-571 572-592 610-630 793-813
signal-regions:
theoretical-pi:7.42
molecular-weight:121449.13
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:10910GenAtlasSLC12A1GenBank Gene DatabaseU58130GenBank Protein Database1373425Guide to Pharmacology968UniProtKBQ13621UniProt AccessionS12A1_HUMAN
synonyms:Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2Kidney-specific Na-K-Cl symporterNKCC2
amino-acid-sequence:>lcl|BSEQ0022479|Solute carrier family 12 member 1 MSLNNSSNVFLDSVPSNTNRFQVSVINENHESSAAADDNTDPPHYEETSFGDEAQKRLRI SFRPGNQECYDNFLQSGETAKTDASFHAYDSHTNTYYLQTFGHNTMDAVPKIEYYRNTGS ISGPKVNRPSLLEIHEQLAKNVAVTPSSADRVANGDGIPGDEQAENKEDDQAGVVKFGWV KGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMVTSITGLSTSAIATNGFVR GGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFAETVVDLLKESDSMMVDPTND IRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAIANFFIGTVIPSNNEKKSRGFFN YQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILAGANISGDLEDPQDAIPRGTMLAIF ITTVAYLGVAICVGACVVRDATGNMNDTIISGMNCNGSAACGLGYDFSRCRHEPCQYGLM NNFQVMSMVSGFGPLITAGIFSATLSSALASLVSAPKVFQALCKDNIYKALQFFAKGYGK NNEPLRGYILTFLIAMAFILIAELNTIAPIISNFFLASYALINFSCFHASYAKSPGWRPA YGIYNMWVSLFGAVLCCAVMFVINWWAAVITYVIEFFLYVYVTCKKPDVNWGSSTQALSY VSALDNALELTTVEDHVKNFRPQCIVLTGGPMTRPALLDITHAFTKNSGLCICCEVFVGP RKLCVKEMNSGMAKKQAWLIKNKIKAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIG YKKNWRKAPLTEIENYVGIIHDAFDFEIGVVIVRISQGFDISQVLQVQEELERLEQERLA LEATIKDNECEEESGGIRGLFKKAGKLNITKTTPKKDGSINTSQSMHVGEFNQKLVEAST QFKKKQEKGTIDVWWLFDDGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKIVMA SLLSKFRIKFADIHIIGDINIRPNKESWKVFEEMIEPYRLHESCKDLTTAEKLKRETPWK ITDAELEAVKEKSYRQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKN LPPVLLVRGNHKNVLTFYS
gene-sequence:>lcl|BSEQ0022480|Solute carrier family 12 member 1 (SLC12A1) ATGTCACTGAACAACTCTTCCAATGTATTTCTGGATTCAGTGCCCAGTAATACCAATCGC TTTCAAGTTAGTGTCATAAATGAGAACCATGAGAGCAGTGCAGCTGCAGATGACAATACT GACCCACCACATTATGAAGAAACCTCTTTTGGGGATGAAGCTCAGAAAAGACTCAGAATC AGCTTTAGGCCTGGGAATCAGGAGTGCTATGACAATTTCCTCCAAAGTGGAGAAACTGCT AAAACAGATGCCAGTTTTCACGCTTATGATTCTCACACAAACACATACTATCTACAAACT TTTGGCCACAACACCATGGATGCCGTTCCCAAGATAGAGTACTATCGTAACACCGGCAGC ATCAGTGGGCCCAAGGTCAACCGACCCAGCCTGCTTGAGATTCACGAGCAACTCGCAAAG AATGTGGCAGTCACCCCAAGTTCAGCTGACAGAGTTGCTAACGGTGATGGGATACCTGGA GATGAACAAGCTGAAAATAAGGAAGATGATCAAGCTGGTGTTGTGAAGTTTGGATGGGTG AAAGGTGTGCTGGTAAGATGCATGCTGAACATCTGGGGAGTCATGCTCTTCATTCGCCTC TCCTGGATTGTTGGAGAAGCTGGAATTGGTCTTGGAGTTCTCATAATTCTTCTTTCCACC ATGGTAACTTCTATTACTGGGTTGTCAACTTCTGCGATAGCAACTAACGGGTTTGTTCGT GGAGGTGGGGCCTACTATCTTATTTCCAGAAGTTTAGGGCCCGAGTTCGGTGGGTCAATA GGCCTGATCTTTGCTTTTGCTAATGCAGTGGCTGTTGCTATGTATGTGGTGGGATTTGCT GAGACTGTAGTAGATCTTCTTAAGGAGAGTGATTCGATGATGGTGGATCCAACCAATGAC ATCCGGATTATAGGCTCCATCACAGTGGTGATTCTTCTAGGAATTTCAGTAGCTGGAATG GAATGGGAGGCAAAGGCCCAAGTCATTCTTCTGGTCATTCTTCTAATTGCTATTGCAAAC TTCTTCATTGGAACTGTCATTCCATCCAACAATGAGAAAAAGTCCAGAGGTTTCTTTAAT TACCAAGCATCAATATTTGCAGAAAACTTTGGGCCACGCTTCACAAAGGGTGAAGGCTTC TTCTCTGTCTTTGCCATTTTTTTCCCAGCAGCTACTGGGATTCTTGCTGGTGCCAATATC TCAGGAGATTTGGAGGATCCCCAAGATGCCATCCCCAGAGGAACCATGCTGGCCATTTTC ATCACCACTGTTGCCTACTTAGGGGTTGCAATTTGTGTAGGGGCCTGTGTGGTCCGAGAT GCCACCGGGAACATGAATGACACCATCATTTCTGGGATGAACTGCAATGGTTCAGCAGCA TGTGGGTTGGGCTATGACTTCTCAAGATGTCGACATGAACCATGTCAGTACGGGCTGATG AACAATTTCCAGGTCATGAGCATGGTATCAGGGTTCGGCCCCCTCATCACTGCGGGAATC TTTTCTGCAACACTCTCCTCCGCCCTGGCCTCCCTTGTCAGCGCACCCAAAGTGTTCCAG GCTCTGTGCAAGGACAACATCTACAAAGCCCTGCAGTTTTTTGCAAAGGGATATGGGAAA AACAATGAACCCCTGAGAGGATATATTCTCACTTTTCTTATAGCCATGGCATTTATTCTT ATTGCGGAACTGAACACCATTGCTCCCATCATCTCCAACTTTTTCCTGGCCTCATATGCA CTTATTAATTTCTCCTGCTTCCATGCCTCTTATGCCAAATCTCCAGGATGGAGACCTGCG TATGGAATTTACAACATGTGGGTATCTCTTTTTGGAGCTGTTTTGTGCTGTGCAGTCATG TTTGTCATCAACTGGTGGGCAGCTGTCATCACCTATGTCATTGAATTCTTCCTTTACGTC TATGTGACTTGTAAGAAGCCAGATGTGAACTGGGGCTCCTCCACACAGGCTCTTTCCTAC GTGAGTGCTTTAGACAATGCTCTGGAATTAACCACAGTGGAAGACCACGTAAAAAACTTC AGGCCCCAGTGCATTGTCTTAACAGGGGGACCCATGACAAGACCTGCTCTCCTGGACATA ACTCACGCCTTTACCAAGAACAGTGGCCTTTGCATCTGCTGTGAAGTCTTTGTGGGACCG CGCAAACTGTGTGTTAAGGAGATGAACAGTGGCATGGCGAAAAAACAGGCCTGGCTTATA AAGAACAAAATCAAGGCTTTTTATGCTGCAGTGGCGGCAGACTGTTTCAGGGATGGTGTC CGAAGTCTTCTTCAGGCCTCAGGCTTAGGAAGAATGAAACCAAACACTCTGGTGATTGGA TATAAGAAAAACTGGAGGAAAGCTCCCTTGACAGAGATTGAGAACTACGTGGGAATCATA CATGATGCATTTGATTTTGAGATTGGCGTGGTTATAGTCAGAATCAGCCAAGGATTTGAC ATCTCTCAGGTTCTTCAGGTGCAAGAGGAATTAGAGAGATTAGAACAGGAGAGACTAGCA TTGGAAGCGACTATCAAAGATAATGAGTGTGAAGAGGAAAGTGGAGGCATCCGAGGCTTG TTTAAAAAAGCTGGCAAGTTGAACATTACTAAGACAACGCCTAAAAAAGATGGCAGCATT AACACAAGCCAGTCGATGCATGTGGGAGAGTTCAACCAGAAACTGGTGGAAGCCAGCACT CAATTTAAAAAGAAACAAGAAAAAGGCACAATTGATGTTTGGTGGTTGTTTGATGATGGA GGGTTAACACTTCTTATCCCCTATATCTTAACTCTCAGAAAAAAATGGAAAGACTGTAAA TTAAGAATCTATGTGGGAGGGAAGATCAACCGCATTGAAGAAGAAAAAATTGTAATGGCT TCCCTTCTGAGCAAATTTAGGATAAAATTTGCAGACATCCATATCATCGGTGACATCAAC ATTAGGCCAAACAAAGAGAGCTGGAAAGTCTTTGAAGAGATGATTGAACCATATCGTCTC CATGAAAGCTGCAAAGATTTAACAACTGCTGAGAAATTAAAAAGAGAAACTCCGTGGAAA ATTACAGATGCAGAACTGGAAGCAGTCAAGGAAAAGAGTTACCGCCAAGTTCGACTGAAT GAACTCTTACAGGAGCACTCCAGAGCTGCTAATCTCATTGTCCTGAGCCTTCCCGTGGCA AGAAAGGGATCCATATCGGATTTGTTGTATATGGCTTGGTTGGAAATCCTCACAAAGAAC CTCCCACCTGTCTTACTAGTTAGAGGAAATCACAAAAATGTCTTGACATTTTACTCTTAA
pfams:PF00324AA_permeasePF03522SLC12PF08403AA_permease_N
go-classifiers:componentapical plasma membranecomponentextracellular exosomecomponentintegral component of plasma membranecomponentmembranecomponentplasma membranefunctionpotassiumfunctionpotassium ion symporter activityfunctionsodiumfunctionsodium ion transmembrane transporter activityprocesscell volume homeostasisprocesscellular hyperosmotic salinity responseprocesschloride ion homeostasisprocesschloride transmembrane transportprocessexcretionprocession transmembrane transportprocession transportprocesskidney developmentprocesspositive regulation of calcineurin-NFAT signaling cascadeprocesspotassium ion homeostasisprocesspotassium ion importprocesssodium ion homeostasisprocesssodium ion transmembrane transportprocesstransmembrane transportprocesstransport
id:BE0000267
name:Carbonic anhydrase 1
organism:Humans
action:inhibitor
Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.
Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential. Laryngoscope. 1998 Apr;108(4 Pt 1):592-8.
Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24.
known-action:unknown
name:Carbonic anhydrase 1
general-function:Zinc ion binding
specific-function:Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
gene-name:CA1
locus:8q13-q22.1
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:7.14
molecular-weight:28870.0
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1368GenAtlasCA1GenBank Gene DatabaseX05014GenBank Protein Database29600Guide to Pharmacology2597UniProtKBP00915UniProt AccessionCAH1_HUMAN
synonyms:4.2.1.1CA-ICABCarbonate dehydratase ICarbonic anhydrase BCarbonic anhydrase I
amino-acid-sequence:>lcl|BSEQ0010047|Carbonic anhydrase 1 MASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEI INVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELH VAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNF DPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAV PMQHNNRPTQPLKGRTVRASF
gene-sequence:>lcl|BSEQ0010048|Carbonic anhydrase 1 (CA1) ATGGCAAGTCCAGACTGGGGATATGATGACAAAAATGGTCCTGAACAATGGAGCAAGCTG TATCCCATTGCCAATGGAAATAACCAGTCCCCTGTTGATATTAAAACCAGTGAAACCAAA CATGACACCTCTCTGAAACCTATTAGTGTCTCCTACAACCCAGCCACAGCCAAAGAAATT ATCAATGTGGGGCATTCCTTCCATGTAAATTTTGAGGACAACGATAACCGATCAGTGCTG AAAGGTGGTCCTTTCTCTGACAGCTACAGGCTCTTTCAGTTCCATTTTCACTGGGGCAGT ACAAATGAGCATGGTTCAGAACATACAGTGGATGGAGTCAAATATTCTGCCGAGCTTCAC GTAGCTCACTGGAATTCTGCAAAGTACTCCAGCCTTGCTGAAGCTGCCTCAAAGGCTGAT GGTTTGGCAGTTATTGGTGTTTTGATGAAGGTTGGTGAGGCCAACCCAAAGCTGCAGAAA GTACTTGATGCCCTCCAAGCAATTAAAACCAAGGGCAAACGAGCCCCATTCACAAATTTT GACCCCTCTACTCTCCTTCCTTCATCCCTGGATTTCTGGACCTACCCTGGCTCTCTGACT CATCCTCCTCTTTATGAGAGTGTAACTTGGATCATCTGTAAGGAGAGCATCAGTGTCAGC TCAGAGCAGCTGGCACAATTCCGCAGCCTTCTATCAAATGTTGAAGGTGATAACGCTGTC CCCATGCAGCACAACAACCGCCCAACCCAACCTCTGAAGGGCAGAACAGTGAGAGCTTCA TTTTGA
pfams:PF00194Carb_anhydrase
go-classifiers:componentcytosolcomponentextracellular exosomefunctionarylesterase activityfunctioncarbonate dehydratase activityfunctionhydro-lyase activityfunctionzinc ion bindingprocessbicarbonate transportprocessone-carbon metabolic processprocesssmall molecule metabolic process
id:BE0000322
name:Carbonic anhydrase 2
organism:Humans
action:inhibitor
Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000.
Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8.
Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24.
known-action:unknown
name:Carbonic anhydrase 2
general-function:Zinc ion binding
specific-function:Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate exchange activity of SLC26A6.
gene-name:CA2
locus:8q22
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:7.47
molecular-weight:29245.895
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1373GenAtlasCA2GenBank Gene DatabaseM77181GenBank Protein Database179780UniProtKBP00918UniProt AccessionCAH2_HUMAN
synonyms:4.2.1.1CA-IICACCarbonate dehydratase IICarbonic anhydrase CCarbonic anhydrase II
amino-acid-sequence:>lcl|BSEQ0018937|Carbonic anhydrase 2 MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRIL NNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHL VHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDP RGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELM VDNWRPAQPLKNRQIKASFK
gene-sequence:>lcl|BSEQ0018938|Carbonic anhydrase 2 (CA2) ATGTCCCATCACTGGGGGTACGGCAAACACAACGGACCTGAGCACTGGCATAAGGACTTC CCCATTGCCAAGGGAGAGCGCCAGTCCCCTGTTGACATCGACACTCATACAGCCAAGTAT GACCCTTCCCTGAAGCCCCTGTCTGTTTCCTATGATCAAGCAACTTCCCTGAGGATCCTC AACAATGGTCATGCTTTCAACGTGGAGTTTGATGACTCTCAGGACAAAGCAGTGCTCAAG GGAGGACCCCTGGATGGCACTTACAGATTGATTCAGTTTCACTTTCACTGGGGTTCACTT GATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGCAGAACTTCACTTG GTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAACCTGATGGACTG GCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTT GATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTTCGATCCT CGTGGCCTCCTTCCTGAATCCTTGGATTACTGGACCTACCCAGGCTCACTGACCACCCCT CCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGCGAG CAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGATG GTGGACAACTGGCGCCCAGCTCAGCCACTGAAGAACAGGCAAATCAAAGCTTCCTTCAAA TAA
pfams:PF00194Carb_anhydrase
go-classifiers:componentapical part of cellcomponentaxoncomponentbasolateral plasma membranecomponentcytoplasmcomponentcytosolcomponentextracellular exosomecomponentextracellular spacecomponentmicrovilluscomponentmyelin sheathcomponentplasma membranefunctionarylesterase activityfunctioncarbonate dehydratase activityfunctionzinc ion bindingprocessangiotensin-activated signaling pathwayprocessbicarbonate transportprocesscellular response to fluid shear stressprocesskidney developmentprocessmorphogenesis of an epitheliumprocessodontogenesis of dentin-containing toothprocessone-carbon metabolic processprocesspositive regulation of bone resorptionprocesspositive regulation of cellular pH reductionprocesspositive regulation of dipeptide transmembrane transportprocesspositive regulation of osteoclast differentiationprocesspositive regulation of synaptic transmission, GABAergicprocessregulation of anion transportprocessregulation of chloride transportprocessregulation of intracellular pHprocessresponse to estrogenprocessresponse to pHprocessresponse to zinc ionprocesssecretionprocesssmall molecule metabolic process
id:BE0000535
name:Carbonic anhydrase 4
organism:Humans
action:inhibitor
Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.
Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24.
known-action:unknown
name:Carbonic anhydrase 4
general-function:Zinc ion binding
specific-function:Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
gene-name:CA4
locus:17q23
cellular-location:Cell membrane
transmembrane-regions:
signal-regions:1-18
theoretical-pi:7.94
molecular-weight:35032.075
chromosome-location:17
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1375GenAtlasCA4GenBank Gene DatabaseM83670GenBank Protein Database179791Guide to Pharmacology2599UniProtKBP22748UniProt AccessionCAH4_HUMAN
synonyms:4.2.1.1CA-IVCarbonate dehydratase IVCarbonic anhydrase IV
amino-acid-sequence:>lcl|BSEQ0001068|Carbonic anhydrase 4 MRMLLALLALSAARPSASAESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTK AKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSD LPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGF QPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFRE PIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKSGAPGRPLPWALPALLG PMLACLLAGFLR
gene-sequence:>lcl|BSEQ0010374|Carbonic anhydrase 4 (CA4) ATGCGGATGCTGCTGGCGCTCCTGGCCCTCTCCGCGGCGCGGCCATCGGCCAGTGCAGAG TCACACTGGTGCTACGAGGTTCAAGCCGAGTCCTCCAACTACCCCTGCTTGGTGCCAGTC AAGTGGGGTGGAAACTGCCAGAAGGACCGCCAGTCCCCCATCAACATCGTCACCACCAAG GCAAAGGTGGACAAAAAACTGGGACGCTTCTTCTTCTCTGGCTACGATAAGAAGCAAACG TGGACTGTCCAAAATAACGGGCACTCAGTGATGATGTTGCTGGAGAACAAGGCCAGCATT TCTGGAGGAGGACTGCCTGCCCCATACCAGGCCAAACAGTTGCACCTGCACTGGTCCGAC TTGCCATATAAGGGCTCGGAGCACAGCCTCGATGGGGAGCACTTTGCCATGGAGATGCAC ATAGTACATGAGAAAGAGAAGGGGACATCGAGGAATGTGAAAGAGGCCCAGGACCCTGAA GACGAAATTGCGGTGCTGGCCTTTCTGGTGGAGGCTGGAACCCAGGTGAACGAGGGCTTC CAGCCACTGGTGGAGGCACTGTCTAATATCCCCAAACCTGAGATGAGCACTACGATGGCA GAGAGCAGCCTGTTGGACCTGCTCCCCAAGGAGGAGAAACTGAGGCACTACTTCCGCTAC CTGGGCTCACTCACCACACCGACCTGCGATGAGAAGGTCGTCTGGACTGTGTTCCGGGAG CCCATTCAGCTTCACAGAGAACAGATCCTGGCATTCTCTCAGAAGCTGTACTACGACAAG GAACAGACAGTGAGCATGAAGGACAATGTCAGGCCCCTGCAGCAGCTGGGGCAGCGCACG GTGATAAAGTCCGGGGCCCCGGGTCGGCCGCTGCCCTGGGCCCTGCCTGCCCTGCTGGGC CCCATGCTGGCCTGCCTGCTGGCCGGCTTCCTGCGATGA
pfams:PF00194Carb_anhydrase
go-classifiers:componentanchored component of external side of plasma membranecomponentapical plasma membranecomponentbrush border membranecomponentcell surfacecomponentendoplasmic reticulum-Golgi intermediate compartmentcomponentextracellular exosomecomponentGolgi apparatuscomponentmembranecomponentperinuclear region of cytoplasmcomponentplasma membranecomponentrough endoplasmic reticulumcomponentsarcolemmacomponentsarcoplasmic reticulumcomponentsecretory granule membranecomponenttrans-Golgi networkcomponenttransport vesicle membranefunctioncarbonate dehydratase activityfunctionzinc ion bindingprocessbicarbonate transportprocessone-carbon metabolic processprocessorgan developmentprocessresponse to drugprocessresponse to steroid hormoneprocesssmall molecule metabolic process

酶

载体

运输工具

药物反应

效应

不良反应